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ABSTRACT 
Background: Brucellosis is a global zoonosis caused by the bacteria of the 
genus Brucella a hazard group III pathogen. Typing of Brucella species is of 
great importance for understanding the epidemiology of the disease and an 
essential tool for the eradication program and vaccine development. The 
aim of the present study is to evaluate Matrix-assisted laser desorption ion-
ization- time of flight spectrometry (MALDI-TOF MS), a proteomic based as-
say, for biotyping B. melitensis in Qatar. 
Methodology: A total of sixty three B. melitensis isolated from clinical spec-
imens, were biochemically identified by Vitek 2 Compact and serotyped us-
ing monospecific Brucella antisera. MALDI-TOF MS Identification was car-
ried out against the newly constructed Brucella library. Subsequently, 
MALDI typing was performed by visual inspection of the generated spectra 
to determine potential biotype-specific marker peaks. Molecular typing was 
performed using B. melitensis biotyping PCR kit as a reference method.  
Results: MALDI-TOF MS identified all the isolates as B. melitensis with a 
score of >2.3 indicating highly probable species identification. The visual in-
spection of the generated spectra revealed six promising marker peaks at 
m/z 4682, 5028, 5970, 6823, 7356, and 7326. The presence or absence of 
these marker peaks grouped the isolates into four groups with four distinct 
marker peak profiles. PCR typing results showed the presence of only two 
biotypes, B. melitensis biotype 2 (n=32) and B. melitensis biotype 3 (n=31). 
The mass spectral profiles that share the marker peak at m/z 7356 (n=32) 
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were confirmed as biotype 2 while the mass spectral profiles that share the 
marker peak at m/z 5970 (n=31) as biotype 3. No B. melitensis biotype 1 was 
detected in this study. 
Conclusion: Human brucellosis in Qatar is exclusively caused by B. 
melitensis with equal distribution of biotype 2 and biotype 3. MALDI-TOF MS 
was found to be a promising tool to identify and differentiate B. melitensis 
biotypes 2 and 3.  Peak at m/z 7356 was identified as biotype 2-specific 
marker peak and peak at m/z 5970 as biotype 3-specific.  
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CHAPTER 1 INTRODUCTION 
1.1 INTRODUCTION 
Brucellosis, also named Mediterranean fever, Malta fever, undulant fever, and 
typhomalarial fever, (Bossi et al., 2004) is a re-emerging zoonosis that has re-
surfaced at the epicenter of scientific interest because of its evolving epidemi-
ology (Pappas, 2010). Human brucellosis caused by an intracellular pathogen 
belong to the genus Brucella, is the most common zoonotic disease worldwide 
with more than 500,000 new cases annually (Buzgan et al., 2009). Although 
sporadic cases are reported from many parts of the world, it is hyperendemic 
in the Mediterranean Basin, Arabian Peninsula, India, Mexico, and Central and 
South America (Buzgan et al., 2009). In Western Europe and North America, 
brucellosis is rare since effective public health measures have been imple-
mented. However, such countries are considering Brucella to be a potential bi-
oterrorism threat leading to an increased interest (Cekovska et al., 2010). In 
addition to the public health importance, brucellosis constitutes a major eco-
nomic problem and causes major economic losses due to time lost by patients 
from normal daily activities and losses in animal production (Dean et al., 
2012). 
Brucella species, a Category B agents, are highly infectious to mammals and 
humans. Currently the genus Brucella comprises ten genetically highly related 
species out of which Brucella  melitensis is the species most frequently re-
ported as a cause of human disease (WHO, 2006). In Qatar, B. melitensis is the 
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etiological agent of Brucellosis with 70-75 cases reported annually (un-
published data QNRF funded study # 5-746-3-176). 
Brucella species, based on their phenotypic and genotypic differences, are fur-
ther differentiated into biotypes (Alton et al., 1975). Typing is important for 
epidemiological purpose, public health and developing strategy for vaccina-
tion. Several conventional and molecular typing techniques are available. Con-
ventional phenotypic typing techniques involve combination of metabolic, bi-
ochemical, and serological tests. However, these tests are not done in most 
clinical laboratories as they require biosafety level 3 facilities, time consuming, 
hazardous to laboratory workers and subjected to variable interpretation 
(Cekovska et al., 2010). On the other hand, molecular typing techniques such 
as Polymerase Chain Reaction (PCR) and Multiple Locus Variable number tan-
dem repeats Analysis (MLVA) have been widely used for identification, classi-
fication and typing of Brucella species (Marianelli et al., 2007; Sayan et al., 
2009). However these techniques are expensive, require molecular setup and 
possess variable discriminatory power (Ranjbar et al.,  2014). In general, dif-
ferentiation of the various species and biotypes of Brucella remains difficult 
and different results can be obtained by independent Brucella research groups 
(Scholz & Vergnaud, 2013). Therefore, development of new techniques that fa-
cilitates a reliable differentiation of the various species and biotypes of Bru-
cella, is of great practical importance. 
Matrix-assisted laser desorption ionization- time of flight spectrometry 
(MALDI-TOF MS), a proteomic based assay, is a promising technique in which 
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a unique mass spectrum with various peaks corresponding to the high-abun-
dance soluble ribosomal proteins is produced for each organism  (Dekker & 
Branda, 2011). This spectrum is compared to a library of spectra produced 
from known reference organisms and the organism’s likely identification is 
provided based on the closest match (Lay, 2001). The advantage of MALDI-
TOF-MS over other conventional and molecular typing methods is that it is fast, 
cost effective, and does not require high skilled personnel (Seng et al., 2009). 
MALDI-TOF MS has been standardized for identification of microorganism but 
only recently studies were conducted for various bacterial typing by analysis 
of the peaks as exemplified for Salmonella enterica (Dieckmann & Malorny, 
2011), and  methicillin-resistant Staphylococcus aureus lineages (Wolters et al., 
2011). 
Ferreira et al (2010) and Lista et al (2011) have reported the reliability of 
MALDI-TOF MS in the identification of Brucella at genus and species level re-
spectively. To our knowledge this is the first study that attempt to use MALDI-
TOF MS for typing of Brucella isolates to the biotype level by identifying bio-
type-specific marker peaks. 
1.2 HYPOTHESIS 
Using biotyper software available in MALDI-TOF (Brucker Daltonics), along 
with standardized typing procedure, we will be able to generate a mass spectra 
with a biotype-specific peaks with reasonable signal intensities to biotype B. 
melitensis. 
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1.3 AIM 
To evaluate MALDI–TOF MS as a safe, rapid, and reliable tool for biotyping of 
B. melitensis. 
1.4 OBJECTIVES 
The objectives of this thesis are: 
1. to construct a Brucella reference library using Brucella reference strains, 
2. to identify the clinical isolates against the newly constructed library, 
3. to generate mass spectra for all clinical isolates and to use these spectra for 
typing, and 
4. to evaluate the relatedness of the species using mass spectrum dendro-
gram. 
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CHAPTER 2 LITERATURE REVIEW 
2.1 BRUCELLA 
2.1.1 Microbiological Characteristics 
Brucella species are facultative intracellular, gram negative coccobacilli or 
short rods that lack capsules, flagella, and endospores (Gwida et al., 2010). Bru-
cella species grow on blood agar plate and chocolate agar but not on Mac-
Conkey, which allow them to be separated from some other Gram-negative 
coccobacilli (Young, 1995). They are slow growers and their growth is often 
improved by carbon dioxide which is essential for some strains. On suitable 
solid media Brucella colonies are visible after 2 days and are 0.5 to 1.0 mm in 
diameter with a convex and circular outline. Smooth strains are transparent 
and pale yellow while rough colonies are more opaque with a granular surface 
(Poester et al., 2010). Brucella species are positive for oxidase, catalase, and 
urease. The metabolism of the Brucella is mainly oxidative and they show little 
action on carbohydrates in conventional media (Al Dahouk et al., 2010). 
2.1.2 Antigenic Components 
The outer cell membrane resembles that of other Gram-negative bacilli with a 
dominant lipopolysaccharide component which is considered the target for 
many serological and immunological studies and the principal virulence factor 
of Brucella (Bossi et al., 2004). All Brucella species, except Brucella ovis and 
Brucella canis, contain smooth lipopolysaccharide (SLPS) in their outer cell 
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wall (Poester et al., 2010). Strains with SLPS are more virulent and more re-
sistant to intracellular destruction by Polymorphonuclear leukocytes than the 
strains with rough lipopolysaccharide (Bossi et al., 2004).   SLPS exist as anti-
genic epitopes A and M which have different quantitative distribution among 
the smooth Brucella strains and are absent, in the rough Brucella strains. This 
is of value in differentiating biotypes of the major species using absorbed mon-
ospecific A and M antisera (Alton et al., 1975). Outer membrane structural pro-
teins (Omp25) are also useful in diagnostic tests. Others, such as ribosomal 
proteins (L7/L12) and fusion proteins, have demonstrated a protective effect 
against Brucella based on antibody and cell mediated responses (Araj, 2010). 
2.1.3 Taxonomy 
The genus Brucella belongs to the family Brucellaceae in the order Rhizobiales 
of the class Alphaproteobacteria (Ficht, 2011) and it contains highly infectious 
species that have been found to cause infections in a wide variety of mammals. 
Species and biotypes classification of Brucella is historically based on natural 
host preference and phenotypic traits (AlDahouk et al., 2010). However mod-
ern taxonomy practices have assisted in further delineating the significance of 
biotypes of the old species and a better understanding of the inter-relatedness 
of all currently described Brucella species (Pappas, 2010). Currently Brucella 
comprises ten species which are further sub-classified into several biotypes as 
shown in Table . The six well recognized species are B. melitensis, biotypes 1-3 
(sheep and goats); B. abortus, biotypes 1-7 and 9 (cattle and other Bovidea); 
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B. suis biotypes 1-5 (biotypes 1-3 pigs, biotype 4 reindeer, biotype 5 small ro-
dents); B. canis (dog); B. ovis (sheep) and B. neotomae (desert wood rats) 
(Lucero et al., 2008). Further, three novel species have been added to the ge-
nus, B. pinnipedialis (seals), B. ceti (dolphins and whales), and B. microti (com-
mon vole, red foxes and also from soil). Most recently B. inopinata isolated 
from a breast implant wound has been described as a new species with so far 
unknown animal reservoir (Al Dahouk et al., 2010). There are two other iso-
lates, with typical Brucella characteristics but distinct from the currently de-
scribed species, known to have caused individual incidences of diseases. These 
isolates still awaiting final taxonomical classification, one being referred to as 
Baboon type in the meantime (Pappas, 2010). 
Human disease severity is to a significant extent determined by the type of 
Brucella to which an individual is exposed. B. melitensis is the type most fre-
quently reported as a cause of human brucellosis and the most virulent type 
that is associated with severe acute disease (WHO , 2006). 
Table 2.1: Provisional Brucella Taxonomy 
 Species Animal host Human disease 
Old species B. melitensis Sheep, goats, 
camels 
The most common cause of 
human brucellosis 
B. abortus Cattle, buffalo, 
elk, yaks, camels 
The second most common 
cause of human infection 
B. suis Domestic pigs, 
wild boar, rein-
deer, caribou, ro-
dents  
Of increasing interest in hu-
man disease, with hunters of 
wild boar at risk 
B. canis Canines Increasing reports, particu-
larly from South America, 
possibly understudied else-
where 
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 Species Animal host Human disease 
B. ovis Sheep Not reported 
B. neotomae Rodents Not reported 
Novel spe-
cies 
B. ceti Porpoises, dol-
phins, whales 
Reports of complicated dis-
ease (neurobrucellosis, 
spondylitis) and one labora-
tory infection 
B. pinnipedi-
alis 
Seals  
B. microti Red foxes, com-
mon voles (also 
isolated from soil 
Not reported 
B. inopinata Unknown Isolated from a human case 
(prosthetic breast implant 
infection) 
Future spe-
cies 
BO2 Unknown Isolated from a human case 
(chronic destructive pneu-
monia) 
Baboon iso-
late 
Baboons Not reported 
Adapted from The changing Brucella ecology: novel reservoirs, new threats by 
Pappas, 2010. International Journal of Antimicrobial Agents. 
 
2.1.4 Clinical Disease 
Brucellosis is a highly transmissible zoonosis that causes a severely debilitat-
ing and disabling illness in human. Human infections arise through direct or 
indirect contact with infected animals or their products that are contaminated 
with these bacteria (Marianelli et al., 2007). The bacteria initially localize in 
the regional lymph nodes, then disseminate haematogenously to the organs of 
the reticuloendothelial system (Memish et al., 2000) leading to a variety of clin-
ical presentations, such as recurrent fever that rise and fall in waves, weight 
loss, general malaise, muscle and joint pain and septicemia (Logan et al., 2011). 
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Signs and symptoms are similar in patients irrespective the route of transmis-
sion and are mostly non-specific which complicate the diagnosis (Bossi et al., 
2004). Brucellosis is usually treated with doxycycline combined with rifampin 
or streptomycin (WHO, 2006). Without adequate and prompt antibiotic treat-
ment, some patients develop a chronic brucellosis syndrome with multiple or-
gans involved and with many features of the chronic fatigue syndrome (WHO, 
2006). Morbidity depends largely upon the speed of diagnosis and the initia-
tion of specific antimicrobial therapy (Al-eissa, 1999). Despite treatment in-
cluding several antibiotic regimens, relapse is estimated to occur in 5–40% of 
patients with acute brucellosis in the following year, depending on antibiotic 
use, duration of treatment, and drug combination (Buzgan et al., 2009). 
2.1.5 Geographic Distribution 
At present, B. melitensis is by far the main cause of clinically apparent disease 
in human worldwide since bovine brucellosis has been successfully eradicated 
(Al Dahouk & Nockler 2011). B. melitensis is fairly widely distributed but is 
particularly occur endemically in the Mediterranean Basin, Arabian Peninsula, 
India, Mexico, and Central and South America (Buzgan et al., 2009). However, 
North America (except Mexico), Northern Europe, Southeast Asia, Australia 
and New Zealand are believed to be free (FAO/WHO, 1997). 
Of the three different biotypes of B. melitensis, biotype 3 predominates almost 
exclusively in Mediterranean countries and Middle East, while biotype 1 seems 
to predominate in Latin America. The biotype 1 and 2 have also been reported 
in some southern European countries (European Commission, 2001). 
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2.1.6 Diagnosis 
The diagnosis of brucellosis should be considered in a patient with fever of un-
known origin and requires the combination of several approaches, including 
medical history, clinical examination, and several laboratory assays (Araj, 
2010). At present, there are various assays for diagnosis of human brucellosis 
such as serological tests that detect anti-Brucella species antibodies, molecular 
methods that detect Brucella species DNA, and the standard microbiological 
tests that attempt to isolate Brucella species (Wang et al., 2014). Knowledge of 
the potentials and limitations of each test are warranted for their appropriate 
application and interpretation. 
2.1.6.1 Serological Diagnostic Tests 
The most commonly serologic tests used in the diagnosis of human brucellosis 
are Serum Agglutination Test (SAT), Rose Bengal test, Coombs’ Test and En-
zyme Linked Immunoassay (ELISA) (Al Dahouk & Nockler, 2011). SAT is the 
reference method in the serological diagnosis of human brucellosis that con-
firms the diagnosis when a single titre >1:160 is found or a four-fold rise in the 
antibody titre is noted between the onset of illness and convalescent-phase se-
rum (Bossi et al., 2004). Serology is fast and non-hazardous, but the lack of 
standardization, cross-reactivity and long-term persistence of significant anti-
body titres after successful treatment may hamper laboratory diagnosis (Al 
Dahouk & Nockler, 2011). In addition adequate cutoff points have to be defined 
for different populations living in regions of varying endemicity to determine 
the significance of positive serologic test results (Al Dahouk & Nockler, 2011). 
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Serological diagnosis is presumptive evidence of infection; therefore, it is es-
sential to correlate the serology findings with clinical signs and symptoms 
(Poester et al., 2010). 
2.1.6.2 Molecular Diagnostic Assays 
Molecular diagnostic assays are used for the direct detection of Brucella from 
clinical specimens, to monitor treatment response, and for the identification 
and differentiation of recovered Brucella species (Poester et al., 2010). These 
assays are based on the amplification of genomic targets through different PCR 
approaches. Genus-specific PCR assays that utilize one pair of primers that am-
plifies and targets a unique and highly conserved genetic loci in all Brucella 
species, like BCSP31gene, 16S rRNA, omp2, Outer membrane proteins (omp2b, 
omp2a and omp31) and IS711, are useful tools for diagnosis in human brucel-
losis (Yu & Nielsen, 2010). Although genus specific PCRs are usually adequate 
for diagnosis of human brucellosis, differential species-specific multiplex PCR 
like AMOS-PCR assay, Bruce-ladder multiplex PCR assay, Arbitrary Primed 
PCR (AP-PCR) or the Random Amplified Polymorphic DNA (RAPD-PCR) can 
also be used for confirmation (Poester et al., 2010). Molecular diagnostic as-
says are reproducible, rapid, and minimize the risk of infection among labora-
tory workers. However, molecular methods are relatively expensive, with var-
iable sensitivity (Al Dahouk & Nockler, 2011), and their efficiency is highly de-
pendent on primers specificity (Wang et al., 2014). Furthermore, molecular 
detection of Brucella DNA does not necessarily indicate the presence of viable 
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organism. Brucella DNA remains detectable in the majority of brucellosis pa-
tients throughout treatment and treatment follow-up, as well as years after 
clinical cure (Al Dahouk & Nockler, 2011). 
2.1.6.3 Standard Microbiological Tests 
Diagnosis is definitively established by the isolation of Brucella from blood, 
bone marrow or body fluids (Al Dahouk & Nockler, 2011). Automated contin-
uously monitored blood culture systems such as Bactec (BD Diagnostics, 
Sparks, MD, USA) and BacTAlert (bioMérieux, Durham, NC, USA) expedite the 
detection of bacterial growth (Araj, 2010). Brucella isolation rates are variable 
depending on the stage of disease, previous use of antibiotics, the clinical spec-
imen and the culture methods (Al Dahouk & Nockler, 2011). Presumptive iden-
tification of Brucella species relies upon basic phenotypic tests such as colonial 
morphology, staining reaction, urease, catalase and oxidase tests. These tests 
can be done by most routine bacteriology laboratories and are the basis for a 
culture to be identified as belonging to the genus Brucella (Poester et al., 2010). 
Once a culture has been identified as Brucella, it is sometimes important to 
classify the species and the biotypes. This further classification should be done 
in specialized or reference laboratories since it is time consuming, hazardous, 
and required highly skilled personnel as well as biosafety level 3 facilities 
(Cekovska et al., 2010). However, bacteriological culture when positive, 
though hazardous and time consuming, is still considered the gold standard 
for human brucellosis diagnosis and is essential for subsequent strain typing 
for epidemiological studies (Hashim et al., 2014). 
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2.1.7 Typing 
The process of differentiating strains based on their phenotypic and genotypic 
differences is known as "typing" (Belkum et al., 2007). Typing of Brucella 
strains is not required to establish a diagnosis but is useful in epidemiological 
studies, understanding the pathogenesis of infection and improving the out-
comes of the national brucellosis eradication program and vaccine develop-
ment (De Santis et al., 2011). 
A wide variety of Brucella typing systems are currently in use that varies 
greatly with respect to cost, reliability, applicability and ability to discriminate 
between different strains. No one technique is optimal for all forms of investi-
gation (Scholz & Vergnaud, 2013). Typing of Brucella strains can be carried out 
by phenotypic and genotypic characteristics analysis. 
2.1.7.1 Phenotyping Methods 
 There are no single definitive phenotypic test that can identify individual Bru-
cella species or biotype. The phenotypic identification of Brucella is based on a 
range of phenotypic tests; by the analysis of the combined results obtained 
from these tests, a fairly confident determination of the Brucella species and to 
a lesser extent the biotype can be made (Appendix C). The most common ap-
plied phenotypic tests are biotyping, serotyping, phage typing and antibiotic 
susceptibility typing (Miljković et al., 2009). 
 14 
 
Biotyping tests include the determination of CO2 requirements, H2S produc-
tion, urease activity, oxidative metabolic pattern, and dye sensitivity (inhibi-
tion of growth on media containing dyes such as thionin or basic fuchsine) 
(Poester et al., 2010). 
Serotyping is based on A and M cell wall lipopolysaccharide antigens detection. 
Both antigens are simultaneously expressed on all smooth Brucella strains. 
Quantitative differences in the amounts of these antigen are thought to account 
for the three phenotypes, A+M-; A-M+; and A+M+, identified by agglutination 
(Bundle et al., 1989). Serotyping is a very subjective test and its cross-reactiv-
ity is well recognized due to the close structural similarities of the A and M 
antigens. In addition, strains converting to the rough phenotype on subculture 
may lose the characteristic agglutination pattern (Dawson et al., 2008). 
Phage typing uses set of  phages that allows definitive identification of smooth 
and rough strains of different Brucella species depending on the characteristic 
lysis of Brucella cultures with these phages (Filippov et al., 2013). The Brucella 
phages currently used for Brucella typing are Tbilisi(Tb), Weybridge (Wb), 
Izatnagar (Iz) and R/C (Filippov et al., 2013). However, Phage typing of Bru-
cella is a multi-day procedure, does not provide differentiation of biotypes and 
the characteristic lysis pattern of smooth Brucella strains may be lost if the 
strains become rough on subculture (Dawson et al., 2008). 
The use of commercially available systems such as Vitek 2 (bioMérieux, 
Durham, NC, USA) for Brucella typing is not recommended because of their 
lack of accuracy, danger of aerosols , and due to the fact that only B. melitensis 
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from the genus Brucella could be identified without  biotype differentiation 
(Cekovska et al., 2010).  
Phenotypic methods in general are time consuming, technically difficult sub-
jected to variable interpretation and most importantly hazardous. Phenotypic 
tests require the isolation of highly infectious pathogen that carries the risk of 
intra-laboratory infection and hence biosafety level 3 precautions must be ob-
served during testing procedure (Cekovska et al., 2010). Another limitation of 
phenotypic typing is the inability to get beyond a partial resolution between 
biotypes (Araj, 2010). 
2.1.7.2 Molecular Genotyping methods 
The genus Brucella is highly homogeneous with all members showing >95% 
homology in DNA–DNA pairing studies (Lucero et al., 2008). Therefore stable 
and specific molecular markers are needed for efficient discrimination be-
tween different Brucella strains. Most molecular typing methods are based on 
the use of a restriction enzyme such as ribotyping; pulsed field gel electropho-
resis (PFGE); and amplified fragment length polymorphism (AFLP). Other 
methods are PCR-based such as  RAPD-PCR; repetitive intergenic palindromic 
sequence-PCR (REP-PCR); AP-PCR ; enterobacterial repetitive intergenic con-
sensus sequence-PCR (ERIC-PCR); polymerase chain reaction–restriction frag-
ment length polymorphism (PCR-RFLP); and multilocus sequence typing 
(MLST) (Bricker et al., 2003). All these techniques possess different discrimi-
natory powers, and their use depends on the final objective to be achieved 
(Whatmore, 2009). 
 16 
 
MLVA is a powerful tool for epidemiological studies of closely related strains 
and has been used very successfully for Brucella genotyping (Sayan et al., 
2009). MLVA based on eight locus scheme, a PCR assay called Hoof-Prints (Hy-
pervariable Octameric Oligonucleotide Fingerprints), is highly discriminating 
and very efficient in distinguishing strains within an outbreak but is unable to 
predict the biotype of an isolate and yet cannot replace conventional biotyping 
methods (Poester et al., 2010). Other assays such as, MLVA-21; MLVA-15; and 
MLVA-16 with higher discriminatory power, were published (Tiller et al., 
2009; De Santis et al., 2011) MLVA-16 assay, for example, consists of eight 
moderate variable minisatellite (panel 1) and eight highly discriminatory mi-
crosatellite (panel 2). The different alleles, amplified by standard PCR tech-
niques, can be then analyzed by several electrophoretic techniques as agarose 
gel, or capillary electrophoresis sequencing (De Santis et al., 2011). However, 
the lack of an international database makes the MLVA typing method inappro-
priate for routine implementation in diagnostic laboratories worldwide 
(Sayan et al., 2009). 
Single-nucleotide polymorphism analysis method for Brucella genotyping on 
the other hand, is found to be promising as the most genetic differences among 
different Brucella species and biotypes consist of single nucleotide polymor-
phisms (Sayan et al., 2009). In general, molecular applications are highly ex-
pensive, time consuming, and sometimes present a low level of reproducibility 
(Whatmore, 2009). 
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2.2 MATRIX-ASSISTED LASER DESORPTION IONIZATION- TIME OF 
FLIGHT SPECTROMETRY (MALDI-TOF-MS) 
2.2.1 Overview 
MALDI-TOF-MS has existed for a long time but it was 1996 when MALDI-TOF 
spectral fingerprints could be obtained from whole bacterial cells for the first 
time (Holland et al., 1999). The same year, Krishnamurthy et al. obtained spec-
tral fingerprints of pathogenic species such as Bacillus anthracis, B. melitensis, 
Yersinia pestis, and Francisella tularensis using MALDI TOF (Carbonnelle et al., 
2011). Ever since, the number of publications concerning not only bacterial 
but also mold and yeast identification increases exponentially. However, use 
of MALDI-TOF in clinical microbiology as a routine first-line identification 
method started just during the past five years (Kostrzewa et al., 2013). 
MALDI-TOF MS technology has fundamentally altered well established diag-
nostic testing methods because of its significant advantages over other con-
ventional and molecular identification methods (Murray, 2012). It is rapid, and 
reliable, it takes only few minutes for correct identification (Fenselau, 2012). 
In addition, MALDI technique is simple, does not require high skilled personnel 
and cost effective (Seng et al., 2009). MALDI TOF MS works well for many bac-
terial species hence has the potential to replace conventional phenotypic iden-
tification for most bacterial strains isolated in clinical Microbiology laborato-
ries (Biswas & Rolain, 2013). 
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2.2.2 Principle 
The intrinsic property of MALDI-TOF MS is to detect the mass-to-charge ratio 
(m/z) of bacterial ribosomal proteins, providing a unique mass spectrum of 
the microorganism within minutes (Carbonnelle et al., 2011). Importantly, 
MALDI approach do not rely on actual identification of the biomarker ion 
peaks in an MS spectrum but on the characteristic mass profile generated by a 
set of ion peaks that constitute a bacterial “fingerprint”(Dieckmann & Malorny, 
2011). 
This method requires that the biopolymer molecules be converted into iso-
lated ionized molecules in the gas phase. These ions are then separated accord-
ing to their molecular weight after migration in an electric field. Each molecule 
detected is characterized by the molecular mass, the charge, and the relative 
intensity of the signal (Carbonnelle et al., 2011). Amass spectrum unique to the 
organism is produced, get compared to a library of spectra obtained from 
known reference organisms, and the organism’s likely identification is pro-
vided based on the closest match (Dekker & Branda, 2011). 
MALDI-TOF MS utilize a soft ionization technique that allows the gentle ioni-
zation and vaporization of large and delicate biological macromolecules into 
the gas phase without extensive sub-fragmentation and without prior purifi-
cation (Dekker & Branda, 2011). Soft ionization of MALDI-TOF have overcome 
the problem of harsh ionization by which only molecules of low molecular 
masses are analyzed (Carbonnelle et al., 2011). 
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MALDI-TOF MS may be used to analyze samples of many types, including solu-
tions of organic molecules, nucleic acids, proteins, and whole microorganisms, 
with the last two being the most useful in present clinical Microbiology appli-
cations (Dekker & Branda, 2011). Fatty acids were evaluated early on as bi-
omarkers for bacterial identification, but rejected as they are too dependent 
on growth and storage condition (Fenselau, 2012). However, the most reliable 
MS biomarkers for bacterial identification are considered to be the major pro-
teins, mainly ribosomal proteins. Ribosomal proteins are abundant, basic, and 
of medium hydrophobicity, all biochemical traits that favor efficient ionization 
(De Carolis et al., 2014). A sufficient number of stable mass signals of these 
proteins(between 2000 Da and 20000 Da) can be detected, yielding profile 
spectra consisting of a series of peaks that are conserved at genus, species and 
subspecies as well (Barbuddhe et al., 2008). 
2.2.3 Sample Preparation 
Two principal bacterial treatment protocols can be used. The first is Direct 
Transfer protocol; based on introducing intact cells onto the MALDI target di-
rectly from agar plates using sterile loops or after harvesting by centrifugation 
from liquid media. The second protocol relies on extraction of bacterial pro-
teins from the cells using different solvents (Sedo et al., 2010). The Direct 
Transfer can be used for 90-95% of routine samples. Extraction is especially 
recommended if very high spectra quality is needed and for very hard to meas-
ure microorganisms where the cell walls are hard or thick and the matrix is 
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not strong enough to break up the cells (Bruker Daltonics, Microflex LT Bio-
typer operating system). In addition, the extraction protocol inactivates a 
broad range of microorganisms. Different solvents are used in extraction ap-
proach with ethanol/formic acid the most used for bacterial identification 
(Bruker Daltonics, Microflex LT Biotyper operating system). 
2.2.4 Technical Description 
The MALDI-TOF MS instrument is composed of three principal units. The first 
is the specimen ionization chamber, within which the laser-based vaporization 
of the specimen takes place; transferring the sample molecule ions into a gas 
phase. The second unit is the time of flight mass analyzer that allows ion sepa-
ration according to m/z. The last unit is the particle detector device that mon-
itor the separated ions (De Carolis et al., 2014). 
The first step is the formation of a crystal between the sample and an organic 
matrix (co-crystallization). The sample is spotted onto a MALDI-TOF sample 
target with an appropriate matrix and allowed to air dry at room temperature 
The matrix is believed to serve two major functions; absorption of energy from 
the laser, and isolation of the analyte molecules from each other (Carbonnelle 
et al., 2011). The matrix is selected for certain properties, including strong ab-
sorbance at laser wavelengths used for ionization, ability to ionize the clinical 
specimen, solubility in solvents that are compatible with the clinical specimen, 
and a complete lack of any chemical reactivity with the clinical specimen to 
avoid unwanted alterations or damage to the measured proteins (Clark et al., 
2013a). A number of such matrix compounds have been developed for use in 
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MALDI-TOF MS, with 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid),  
α-cyano-4-hydroxycinnamic acid (α-CHCA) and 2,5-dihydroxybenzoic acid 
(DHB) being the most commonly used in bacterial identification (De Carolis et 
al., 2014). Each matrix has a unique initial velocity when exposed to a pulsed 
laser beam under vacuum. For example, α-CHCA, often referred to as a hot ma-
trix, has a high initial velocity (Olsen & Macek, 2009). 
After co-crystallization of the sample and matrix, the target is loaded into the 
specimen ionization chamber, where the sample-matrix mixture is pulsed with 
a laser. Ultraviolet nitrogen lasers (337 nm) is usually used in MALDI-TOF ap-
plications, although other types of lasers can be used as well (Dekker & Branda, 
2011). The supplied laser energy is so high that the matrix and the analyte are 
sublimated directly from the solid phase into the gas phase (Bruker Daltonics). 
The matrix absorbs energy from the laser resulting in vibrational excitation of 
the matrix and the ejection (desorption) of analyte molecules surrounded by 
clusters of matrix molecules, water, and ions (Clark et al., 2013b). Once de-
sorbed, the matrix molecules transfer protons to the analyte, resulting in pos-
itively charged analyte cations in the gas phase. The most common MALDI ion-
ization format is for analyte molecule to carry single positive charge (Dekker 
& Branda, 2011). The gas phase analyte cations are then accelerated across an 
electric field within the ionization chamber to a velocity that depends on the 
mass-to-charge (m/z) ratio of the analyte (De Carolis et al., 2014). 
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The ions leave the ionization chamber and enter the high vacuum flight tube 
(TOF) with smaller ions traveling faster than larger ones before hitting the de-
tector located at the other end of the tube. Thus, the time of flight (TOF) re-
quired to reach the detector is dependent on the mass and charge of the ion 
(De Carolis et al., 2014). The impact of ions at the detector generates an elec-
trical signals. These signals are analysed by software and displayed as a spec-
trum that is characterized by both the m/z and the intensity of the ions, which 
is the number of ions of a particular m/z that struck the detector (Croxatto et 
al., 2012). The time of ions transmission is measured precisely by their arrival 
at the mass detector and their m/z is determined with the help of a calibration 
curve that blot the flight time against m/z (Bruker Daltonics, Microflex LT Bi-
otyper operating system). Mass spectra are then searched for in the appropri-
ate database for the identification of the microorganism, comparing with val-
ues provided by database (Cobo, 2013). 
2.2.5 Biotyper Software and Database 
MALDI-TOF MS Biotyper software has three main components. MALDI Bio-
typer Real time Classification (RTC) for quick classification of unknown sam-
ples, MALDI Biotyper Offline Classification (OC) for advanced classification 
process and investigate the relationships between groups of organisms, and 
Flex Control Used to control the MALDI-TOF instrument. MALDI Biotyper da-
tabase (Bruker Daltonics, Leipzig, Germany) used for routine identification of 
microorganism in clinical Microbiology contains database for wide variety of 
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clinically relevant microorganisms, involving bacteria and fungi, but some im-
portant pathogens like Brucella, have not been yet included in the database 
(Ferreira et al., 2010). However, the Biotyper software is an open platform al-
lowing the user to save runs to expand the database of stored spectra by uti-
lizing tools included in the software. The user also has the ability to create main 
spectra with the assistance of the software (Clark et al., 2013a). 
2.2.6 Microorganism Identification 
For microorganism identification, mass spectra are generated and analyzed 
with regard to spectrum peak frequency, position, and intensity against a data 
base of reference spectra referred to as the MALDI biotyper library (MBL) in a 
real time manner via the Biotyper RTC software (Clark et al., 2013a). MBL in-
clude species-specific fingerprints of several bacterial and yeast isolates. 
Through a pattern matching procedure, mass peaks in the unknown spectra 
are matched with reference spectra included in the database. Level of similar-
ity between the acquired unknown spectra and MBL entries' is calculated as a 
score ranging from 0.00 indicating no similarity to 3.00 indicating a perfect 
match (De Carolis et al., 2014). A log score ranging from 2.3 to 3.000 is inter-
preted by the software as a highly probable species-level identification., log 
scores between 2.00 and 2.299 , genus identification and probable species-
level identification and log scores ranging from 1.70 to 1.999 represent a prob-
able genus identification. Log scores below 1.699 to 0 are not considered to be 
a reliable identification (Clark et al., 2013a). De Carolis et al (2014) found that 
the overall MALDI-TOF identification performance (93.2%) is significantly 
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better than that of BD Phoenix's (75.6%) (Becton Dickinson Diagnostic Sys-
tems, France) and Vitek 2's (75.2%) (BioMérieux, Marcy L'Etoile, France). The 
accuracy of the identification depends greatly on the number of database en-
tries. An update of the reference database is needed to improve the identifica-
tion performance of MALDI-TOF (De Carolis et al., 2014). The reproducibility of 
mass patterns is sensitive to sample culture, preparation, storage, and the kind 
of mass matrix used (Fenselau, 2012). 
2.2.7 Microorganism Typing 
MALDI-TOF spectrometry method has been recently used as a tool for classifi-
cation and subtyping of bacteria. While MALDI-TOF identification of bacteria 
at genus and species levels has been shown clearly to be rapid and effective, 
the utility of this approach at the strain level has not been completely explored 
and lack approved guidelines for data interpretation (Sandrin et al., 2012).  
Identification to the more specific ‘‘strain’’ requires higher resolution ap-
proaches and tends to be more challenging, because strains within a single spe-
cies are quite often extremely similar, genotypically and phenotypically 
(Sandrin et al., 2012). There are few studies published on potential use of 
MALDI for epidemiological typing and it is not clear if MALDI-TOF MS typing 
will be as successful as identification. Strain typing by MALDI-TOF MS was re-
ported in recent studies on S.  enterica (Dieckmann & Malorny, 2011), methi-
cillin-resistant S. aureus lineages (Wolters et al., 2011), Streptococcus agalac-
tiae ( Lartigue et al., 2009)  ,and  Yersinia enterocolitica (Rizzardi et al., 2013). 
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MALDI-TOF MS Bacterial typing at the strain level utilizes different ap-
proaches. One is strains categorization without providing discrimination of 
single strains using  mass spectrometry-based dendrograms, in which closely 
related strains are separated hierarchically according to their mass signals and 
intensities (De Carolis et al., 2014). In contrast, strain differentiation based on 
distinguishing single strains from one another by the presence and/or absence 
of one or more discriminating peaks (Sandrin et al., 2012). However, this ap-
proach is subjected to analytical error, biological, and technical variation(Spi-
nali et al., 2014). A third approach perform strain identification by comparing 
profiles of unknown strains to those in the reference strains (Sandrin et al., 
2012). 
2.2.8 MALDI TOF MS and Brucella 
There has been considerable interest in using MALDI-TOF MS for the identifi-
cation of fastidious organisms and potential agents of bioterrorism. Ferreira et 
al (2010) and Lista et al (2011) has reported the reliability of MALDI-TOF in 
the identification of Brucella species at genus and species level respectively. An 
important problem for the routine use of MALDI-TOF MS for identification of 
Brucella species is that there is no reference library for Brucella incorporated 
to the main databases, because of problems derived from their potential bio-
terrorist use (Ferreira et al., 2010). A recent study reported that MALDI could  
reliably identify 92% of the Brucella isolates at species level,  but incorrect bi-
otype assignments were frequently found (Karger et al., 2013).   
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CHAPTER 3 MATERIALS AND METHODS 
3.1 List of Reagents 
1. B. melitensis biotype 1 strain 16M (NCTC10094). 
2. B. melitensis biotype 2 strain 63/9 (NCTC10508). 
3. Brucella abortus biotype 1 (NCTC10093). 
4. B. abortus monospecific antiserum, 1 ml/vial (USDA, National Vet-
erinary Service Laboratory [NVSL], Ames; catalog #A12 Center for 
Disease Control) , reconstitute with 1 ml of distilled water and store 
2-8° C. 
5. B. melitensis monospecific antiserum, 1 ml/vial (NVSL; catalog 
#M12-CDC), reconstitute with 1 ml of distilled water and store 2-
8° C. 
6. Qiagens mericon DNA Bacteria Kit. 
7. B. melitensis biotype typing PCR kit (Ankara University Biotechnol-
ogy Institute, Ankara Turkey). 
8. Absolute Ethanol (Fisher Scientific, Loughborough, UK). 
9. 70% Formic Acid. 
10. 100% Acetonitrile. 
11. α-cyano-4-hydroxycinnamic acid (α HCCA, Bruker Daltonics) 
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3.2 Ethical Approval 
Ethical approval was obtained from the Medical Research Center at Hamad 
Medical Corporation, protocol number 14383/14 (Appendix A & B). 
3.3 Safety Precautions 
All cultures were processed in a Class III biological safety cabinet in a negative 
pressure room using the appropriate personnel protective equipment. All tests 
were performed with attention to avoid the creation of dangerous aerosols, 
which is very important for laboratory safety. Recommended extraction 
method was performed to ensure safety of testing personnel and instrument 
contamination. 
3.4 Bacterial Strains and Sample Size 
3.4.1 Reference Strains 
Three reference Brucella strains were used in this study as shown in Table 3.1. 
The strains were obtained from National Collection of Type Cultures (NCTC, 
Public Health England, UK). 
B. melitensis Ether- biotype 3 strain (NCTC10509) was not available with NCTC 
and was not included in the study. 
Table 3.1: Reference strains included in the study 
Species/Subspecies Type Strain 
B. abortus biotype 1 NCTC10093 
B. melitensis 16M biotype 1 NCTC10094 
B. melitensis 63.9 biotype 2 NCTC10508 
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3.4.2 Clinical Isolates 
A total of 63 Brucella isolates were obtained from Microbiology Biobank, De-
partment of Microbiology at Hamad Medical Corporation. Brucella strains 
were originally isolated from positive cultures of patients attending Hamad 
Medical Corporation in the period of 2012-2013 (Patient demographics are 
shown in Table.2). All strains were presumptively identified at genus level in 
the clinical Microbiology laboratory on the basis of colonial morphology, mi-
croscopic appearance, showing Gram-negative coccobacilli, and biochemical 
properties like oxidase and catalase production after which they were cryo-
preserved in cryovials with beads & glycerol (mastcryobank, Mast Group Ltd, 
UK) and stored at -80° C. 
Table 3.2: Demographic data of the study population 
Characteristic Number of Patients 
All subjects 63 (100%) 
Age group   
<12 15 (23%) 
12–60 41 (66%) 
>60 7 (11%) 
Gender  
Male 54 (86%) 
Female 9 (14%) 
Nationalities  
Qatari 31 (49%) 
Arabian Peninsula (Saudi Arabia, Yemen) 4 (6%) 
Asians (Bangladesh, India, Sirilanka, Nepal) 10 (16%) 
Egypt 5 (8%) 
Sudan 5 (8%) 
Others (Iraq, Jordan, Syria, Mauritania, Eritrea) 8 (13%) 
 29 
 
3.5 Bacterial Reviving 
All the clinical isolates from frozen cryovials as well as the three reference 
strains were cultured on sheep blood agar plates and incubated in aerobic con-
ditions at 35°C in the presence of 5% CO2 for 48 hours. The growing bacteria 
were then sub-cultured on sheep blood agar, incubated for 48 hours at 35° C 
in the presence of 5% CO2. The sub-cultured bacteria were numbered as BRUC 
(1-63) and used for the subsequent testing. 
3.6 Identification with Vitek 2 Compact 
Identification of all clinical isolates to species level was done with Vitek 2 com-
pact (bioMérieux, Durham, NC, USA) using gram negative (GN) cards. Bacterial 
suspensions were prepared in normal saline and adjusted to 0.5 McFarland. 
Tubes were then sealed to avoid the creation of dangerous aerosols, cards 
were inserted and the tube-card sets were loaded into Vitek 2 compact for 
identification. 
3.7 Serological Typing 
All the clinical isolates that have been identified with Vitek 2 compact were 
further classified into different biotypes using A and M Brucella monospecific 
antisera provided by National Veterinary Service Laboratory (NVSL), USA.   
Actively growing cultures of reference strains and clinical isolates were used 
to prepare heavy suspension (equivalent to 2 McFarland) in 1 ml of phenolized 
saline in screw-cap tubes. Tubes were then incubated for 1 h in a 65° C water 
bath to deactivate the bacteria.10 µl of each A and M monospecific Brucella 
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antiserum was placed on a microscope slide and equal volume of organism 
suspension was added to each and mixed with an inoculating loop. After gentle 
shaking, agglutination reaction was examined within 1 minute. Positive results 
were obtained when agglutination of bacterial inoculum with antiserum oc-
curred within 1 minute of mixing. Negative result on the other hands were con-
sidered when bacterial inoculum failed to agglutinate within 1 minute of mix-
ing with antiserum. Identification of biotypes were made using Table 3.3 in 
Appendix C. Controls used were as follows: Brucella abortus biotype 1 
(NCTC10093) agglutinates only with A antisera and B. melitensis biotype 1 ag-
glutinates only with M antisera. 
3.8 MALDI-TOF MS 
Microflex LT Biotyper operating system (Bruker Daltonics, Bremen Germany) 
and Bruker Biotyper 3.0 software were used in the study. 
3.8.1 Sample Preparation and Formic Acid Extraction 
All the three reference strains as well as the 63 clinical isolates were prepared 
using Formic Acid Protein extraction method, which reliably killed the bacte-
ria, in accordance with the company guidelines. Two extracts were generated 
from independent subcultures. Around 10 colonies were suspended in 300 μl 
of water and mixed well by vortexing to generate a homogeneous suspension. 
900 μl of absolute ethanol was added and the suspension was mixed carefully. 
The suspension was left for 90 minutes at room temperature to inactivate all 
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of the bacteria after which it was centrifuged for 2 min at 13,000×g. The super-
natant was removed. The spinning step was repeated and all the residual eth-
anol was removed by pipetting. The pellet was kept at room temperature for 
drying. Next, 50 μl of 70% formic acid was added to the pellet, and the pellet 
was mixed thoroughly for 2 minutes. Subsequently, an equal volume of 100% 
acetonitrile was added and mixed carefully. This allows the release of the cells 
contents into the supernatant. The particulate matter that could not be dis-
solved was spun down by centrifugation for 2 min at 13,000×g. The superna-
tant was then spotted onto a MALDI-TOF target plate and used for main spec-
tra projection (MSP) creation, real time classification (RTC) and typing. 
3.8.2 Target Plate Preparation: 
Spots were created, using 0.1 μl of the supernatant per spot, onto a MALDI-TOF 
target plate (MTP 96 target, Bruker Daltonics) and air-dried. Subsequently, the 
spots were overlaid with 0.1 μl of α-cyano-4-hydroxycinnamic acid (CHCA, 
Bruker Daltonics) and dried at room temperature. The number of spots cre-
ated differs as per the analysis performed (Table ). 
Table 3.3: Number of spots per Analysis 
Analysis Number of spots 
MSP creation 8 spots 
Real time Classification RTC (Identification) 2 spots 
Typing 2 spots 
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3.8.3 Mass Spectra Acquisition 
All of the mass spectra were automatically acquired on a Bruker flex control in 
linear, positive mode at laser frequency of 60 Hz and laser intensity of 35%. 
The acceleration voltage was 20 kV and 18.7 kV for source voltage. For each 
spectrum, 240 laser shots in 40-shot steps from different areas of the sample 
spot were accumulated and analyzed (in automatic mode using default set-
tings). The mass spectra were recorded at a mass/ charge range of 
2000-20,000 Da for MSP creation and between 0 and 30,000 Da for typing. 
3.8.4 Calibration 
The instrument was calibrated using Bruker bacterial test standard BTS 
(Bruker part no. #255343), an extract of Escherichia coli DH5a which has been 
spiked with two additional proteins. Calibration was performed with each tar-
get slide following manufacturer’s instruction. The Err/ppm column for each 
calibrant was checked, for the value which must not exceed ±300ppm. Once 
the calibration was achieved, the calibration values were saved and were fur-
ther applied to the measurement of clinical experimental strains. 
3.8.5 Quality Control 
Positive and negative controls were included in each run. BTS was used as pos-
itive control while blank spot was used as negative controls. Furthermore, by 
including reference strains during each extraction procedure, the complete 
procedure was validated. Quality control criteria to qualify or disqualify a run 
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was set. BTS should yield an identification of Escherichia coli with log scores 
>2.30 and blank should yield no peak. 
3.8.6 MSP Creation and Library Construction 
Extracts from reference strains were used to create Main Spectra Projection 
(MSP). Eight spots were created using the procedure explained in target prep-
aration (see 3.8.2 Target preparation). Target plate was loaded into the mass 
spectrometer. Spectra were generated using Bruker FlexControl (see 3.8.5 
Mass spectra acquisition). Toward the goal of improving reproducibility, the 
eight spots were run three times and a total of 24 MS spectra were obtained 
for each strain. To ensure accuracy, two spots of freshly prepared BTS were 
included in each run (one BTS spot was used for calibration and the other was 
used as control for the standard curve). The obtained raw spectra for the three 
reference strains were manually processed using FlexAnalysis software. 
Smoothing and baseline subtraction were performed. The quality of individual 
raw spectrum measurements was carefully checked. Peaks of very weak inten-
sity or too intense peaks were considered outliers and were excluded. Peaks 
deviation were checked by calculating the difference between the highest and 
lowest signal of particular peak. If the difference was more than 500 ppm, the 
spectrum of the deviated peak was discarded. Maximum of four spectra can be 
discarded. The processed spectra were then used to create MSP using the au-
tomated MSP creation functionality of the MALDI Biotyper 3.0 software. For 
each MSP, a minimum of 20 independent processed peaks were used to create 
main spectrum containing the information about mean peak masses, mean 
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peak intensities, and mean peak frequencies. The created MSPs were used to 
construct the Brucella library following the manufacturer's instructions. Each 
individual spectrum was then run against the MSP for that isolate to ensure 
that the identification scores were >2.3 for all spectra incorporated into the 
MSP. As a validation step, each created MSP was run later against a database 
consisting of 34 Brucella species mass spectra profiles that was obtained from 
the Special Pathogen Branch at CDC, Atlanta, USA. 
3.8.7 MALDI-TOF MS Identification  
Extracts from clinical isolates were used in this step. 2 spots were created, us-
ing the procedure explained in Target preparation (see 3.8.2 Target prepara-
tion). Target plate was loaded into the mass spectrometer. MALDI Biotyper 
RTC was started and MALDI Biotyper Real time Classification Wizard was 
launched. A new project was created and sample data were entered.  
The obtained spectra were analyzed against three libraries: 
 The Standard Bruker Reference Library (>5600 entries) to check if the 
obtained Brucella spectra matched any other bacterial spectra. 
 The newly constructed Brucella library (3 reference MSPs) to validate the 
newly constructed library. 
 The Brucella database provided by the Special Pathogen Branch at CDC, 
Atlanta, USA to validate the classification results. 
The degree of spectral concordance was expressed as a logarithmic identifica-
tion score ranging from 0 to 3 and was interpreted according to the manufac-
turer’s instructions.  
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3.8.8 MALDI-TOF MS Typing 
Extracts from reference strains as well as clinical isolates were used to create 
two spots using the procedure explained in Target preparation (see 3.8.2 Tar-
get preparation). Target plate was loaded into the mass spectrometer. Spectra 
were generated using Bruker flex control (see 3.8.5 Mass spectra acquisition). 
The two spots were run three times and a total of six MS spectra were obtained 
for each bacterium. Toward the goal of improving reproducibility, two inde-
pendent runs were performed (the whole typing procedure was repeated 
twice). To ensure accuracy, one spots of freshly prepared BTS were included 
in each run as a control. 
The obtained raw spectra were manually processed using FlexAnalysis soft-
ware. After smoothing and baseline subtraction, potential biomarker peaks 
were identified by visual inspection of the mass spectra by FlexAnalysis (over-
laid view). As the actual biotypes of the clinical isolates were unknown at the 
time of analysis, rules for selecting a biomarker peaks were set and an individ-
ual spectral analysis was performed. A Mass signal to be considered as biotype-
specific peak should be recorded consistently in all spectra of a particular iso-
late with reasonable intensity (>1000 au) to avoid false interpretation (Spinali 
et al., 2014). Consistency of a peak recording means that the peak either pre-
sent or absent in the biotype of choice within a m/z of ±5 range (Clark et al., 
2013a), and exhibiting the opposite condition in all other biotypes. Typically, 
when two different biotypes were compared, several potentially biotype-dis-
criminating peaks per spectrum were observed, of which usually several were 
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present in more than one biotype. Therefore, common peaks were excluded 
and the spectra were carefully inspected for reproducible biotype-specific 
markers. Promising markers were selected accordingly and evaluated for their 
usage to discriminate biotypes. Attempts to identify the different acquired 
peak profiles was carried out by comparing the marker peak profiles of the 
study isolates with the reference strains.  
3.8.9 MSP Dendrograms Creation  
MSPs were created for all the clinical isolates following the same procedure 
described in MSP creation for reference strains. The generated MSPs were 
used to perform a hierarchical clustering of strains using the MSP dendrogram 
tool of the MALDI Biotyper 3.0 software to infer the relationships of Brucella 
species or strains, the closeness of which is reflected by an arbitrary distance 
level calculated by the software. 
3.9 Molecular Typing 
3.9.1 DNA Extraction 
DNA was extracted from the clinical isolates as well as the reference strains 
using Qiagens mericon DNA Bacteria Kit following the manufacturers recom-
mended procedure. Colonies were suspended in 1 ml RNAase free water in 
1.5 ml microcentrifuge tube. The suspension was then centrifuged at 13,000×g 
for 5 minutes. The supernatant was discarded ensuring that all liquid is com-
pletely removed without disrupting the pellet. The pellet was resuspended 
with the 400 µl of lysis buffer and vortexed vigorously for at least one minute. 
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The samples were then heated using heat block at 100° C for 10 minutes. Tubes 
were centrifuged at 13,000×g for 5 minutes.100 µl of the supernatant was 
transferred to fresh 1.5 ml microcentrifuge tube. 
3.9.2 DNA Concentration and Purity Determination 
The DNA concentration of the extracted DNA was determined using Nano Drop 
Spectrophotometer; all assays were performed according to the manufacture 
instructions using 1 µl of extracted DNA for each measurement. The concen-
tration of DNA was calculated based on the approximation that an absorbance 
reading of 1 µl of the purified DNA at 260nm was taken to correspond to 
50 ng/µl. DNA purity was estimated by determination of the A260/A280 ratio 
and reference value for purity was found to be1.8. Samples were stored at 4° C 
until analysis. 
3.9.3 PCR Amplification and Gel Visualization 
Samples identified as B. melitensis were analyzed using a B. melitensis biotype 
typing PCR kit (Ankara University Biotechnology Institute, Ankara Turkey). 
For this purpose, 2.5 μl of DNA extract was added to 17.5 master mix (9 μl 
SYBER Green, 9.5 μl water and 2 μl primer mix reverse and forward primers). 
Following polymerase activation (94° C for 2 min), 40 cycles were run with 
45 s denaturation at 94° C, 45 s annealing at 58° C, and 45 s extension at 72° C 
(Table ).The PCR products (10 μl) were separated by 1.5% agarose gel electro-
phoresis and visualized with the BIO-RAD Gel Doc XR+ system. Reference 
strains for biotype 1 and 2 were included in each run. 
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Table 3.4: RT-PCR Cycling Conditions 
Step Time Temperature 
Number of Cy-
cles 
Initial polymerase activation 2 min 94° C - 
Denaturation 45 sec 94° C 40 x 
Annealing 45 sec 58° C 
Extension 45 sec 72° C 
 
3.10 Statistical Analysis 
Descriptive statistics in the form of frequency and percentages were per-
formed. Associations between the marker peaks and biotypes were assessed 
using Pearson chi-square test and Fisher's Exact Test. The measure of associa-
tion phi and Cramer’s V were computed to compare the strength of association 
between the marker peaks and biotypes. 
Kappa measure of agreement was computed to assess the agreement between 
MALDI-TOF -typing, serotyping and PCR. All Statistical analyses were done us-
ing statistical packages IBM SPSS and P values (0.05) two tailed were consid-
ered as statistically significant. 
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CHAPTER 4 RESULTS 
4.1 Identification with Vitek 2 Compact 
All the 63 clinical isolates were identified as B. melitensis with a probability of 
99% and excellent confidence level using Vitek 2 compact (Appendix D). 
4.2 Serological Typing 
Of the 63 isolates, 42 (66.6%) were serotyped as B. melitensis biotype 1, 14 
(22.2%) were B. melitensis biotype 2, and 7 (11.11%) were B. melitensis bio-
type 3 as shown in Table . Brucella abortus biotype 1 (NCTC10093) and B. 
melitensis 63.9 biotype 2 gave agglutination reaction only with M while B. 
melitensis biotype 1 (NCTC10094) gave agglutination reaction only A antisera 
as shown in Table 4.2. Serotyping results of the isolates are shown in Appendix 
D. 
Table 4.1: Summary of Serotyping Results of B. melitensis Isolates 
Biotype 
Agglutination with Mono-
specific antisera Number of iso-
lates 
A M 
B. melitensis biotype 1 - + 42 (66.6%) 
B. melitensis biotype 2 + - 14 (22.2%) 
B. melitensis biotype 3 + + 7 (11.11%) 
Table 4.2: Serotyping Results of the controls 
Analyte Name 
Serology 
A M 
B. abortus  biotype 1 (NCTC10093) + - 
B. melitensis 16M biotype 1 (NCTC10094) - + 
B. melitensis 63.9 biotype 2 (NCTC10508) + - 
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4.3 MALDI-TOF MS 
4.3.1 Quality Control 
BTS used as positive control yield an identification of Escherichia coli with log 
scores >2.30. Blank spot used as negative controls yield no peak. 
4.3.2 MSP Creation and Reference Library Construction 
MSPs were created successfully for all reference strains, and new Brucella MSP 
library was constructed as shown in Table. 
When each individual spectrum was run against the MSP for that isolate, an 
identification scores of >2.3 for all spectra incorporated into the MSP were ob-
tained (Table). 
When each created MSP was run against a database obtained from the Special 
Pathogen Branch at CDC, all spectra were correctly identified with a scores of 
>2.00. 
Table 4.3: The Identification of Reference Strains against the Newly Con-
structed Brucella MSP Database 
AnalyteName 
Organism(best 
match) 
Score 
Value 
B. abortus  biotype 1 (NCTC10093) B. abortus 2.485 
B. melitensis 16M biotype 1 (NCTC10094) B. melitensis 2.494 
B. melitensis 63.9 biotype 2 (NCTC10508) B. melitensis 2.432 
4.3.3 MALDI-TOF MS Identification  
When the spectra for all the clinical isolates were analyzed against the Stand-
ard Bruker Reference Library, that lack Brucella reference MSP, no reliable 
identification was obtained for any of the spectra. 
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However, when the spectra were analyzed against the newly constructed Bru-
cella library and the database provided by the CDC, correct identifications at 
species level were obtained. All were identified as B. melitensis with a score of 
>2.3 indicating highly probable species identification (Appendix E). 
Conversely, identification to biotype level gave inconsistent results and differ-
ent biotype assignments were frequently found. Identification to biotype level 
was carried against the acquired CDC library but not against the limited newly 
constructed library that lack biotype 3 reference strain spectral profile.  
4.3.4 MALDI-TOF MS Typing 
After careful visual inspection of the obtained spectra (six for each isolate) us-
ing FlexAnalysis (overlaid view), several potential marker peaks per spectrum 
were observed. After excluding the common peaks, ten promising marker 
peaks (m/z values) in a range of m/z of 2500 to 7500 were identified. Four of 
the ten identified m/z values were found to represent doubly-charged ions of 
molecules, whose singularly-charged counterparts were also detected and do 
not add additional information for strain differentiation. These doubly-
charged ions at m/z 2512, 3411, 3663, and 3678 were excluded from the anal-
ysis. The remaining six potential marker peaks were of m/z 4682, 5028, 5970, 
6423, 7326, and 7356 within a range of ±5 m/z differences (Figure 4.1) and 
(Figure 4.2). These peaks were with intensity >1000 au, reproducible in the 
sense that the signal was consistently present or absent in all the six spectra 
obtained for the same isolate, and discriminating in the sense that they were 
not detected in all isolates and thus were incorporated into the typing scheme. 
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Analysis of all spectra for the presence or absence of the selected potential 
marker peaks revealed four distinct marker peak profiles dividing the isolates 
into four groups as seen in Table . Group 1(n=24) had only one marker peak at 
m/z 7356; Group 2 (n=8) had combination of three marker peaks at m/z 7356, 
5028 and 4682; Group 3 (24) had two marker peaks at m/z 6823 and 5970; 
and Group 4 (n=7) had two marker peaks at m/z 7326 and 5970. 
The marker peak profiles of the four groups were compared with the marker 
peak profiles of the reference strains (Table 4.5). It was observed that, marker 
peak at m/z 7356, present in B. melitensis biotype 2 reference strain, was pre-
sent in groups 1 and 2. However, the other two extra marker peaks (m/z 4682 
and 5028) seen in group 2 were not present in B. melitensis biotype 2 reference 
strain. Marker peaks at m/z 5970 and 7326, present in B. melitensis biotype 1 
reference strain, were present in group 4. However, marker peak at m/z 5970 
was also present in group 3 along with marker peak at m/z 6823. 
Based on the comparison of the presence or absence of peaks in groups (1-4) 
with the peaks present in reference strains, three MALDI-types were identi-
fied. Groups 1 (showing complete peak match with biotype 2 reference strain) 
and group 2 (showing extra but not less peaks than biotype 2 reference strain) 
were considered of one type as both shared the marker peak at m/z 7356 that 
represent B. melitensis biotype 2 (NCTC10508), and were referred as MALDI-
type2. Group 4 was comparable to B. melitensis biotype 1 (NCTC10094) and 
was referred as MALDI -type1. The lack of reference strain B. melitensis biotype 
3 mass spectral profile hampered the analysis of the third group but as it 
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showed different peaks combination, it was considered a third type and was 
referred as MALDI-type 3 (Appendices F-J). 
The different marker peak profiles of the four groups were evident on gel view 
created using Biotyper 3.0 software (Figure 4.3). 
Table 4.4: The Four Distinct groups obtained by MALDI-typing 
Marker Peaks 
(m/z) 
Group 1 
(n=24) 
Group 2 
(n=8) 
Group 3 
(n=24) 
Group 4 
(n=7) 
4682 - + - - 
5028 - + - - 
5970 - - + + 
6823 - - + - 
7326 - - - + 
7356 + + - - 
MALDI-type MALDI-type 2 MALDI-type 2 MALDI-type 3 MALDI-type 1 
 
Table 4.5: Marker peak profiles for the Reference Strains 
Peaks (m/z) 
B. melitensis biotype 
1 (NCTC10094) 
B. melitensis biotype 
2 (NCTC10508) 
B. melitensis biotype 
3 (NCTC10509) 
4682 - -  
 
Not Available 
 
5028 - - 
5970 + - 
6823 - - 
7326 + - 
7356 - + 
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(A) 
 
(B) 
 
(C) 
 
(D) 
 
(E) 
 
(F) 
 
(G) 
 
(H) 
 
Figure 4.1: The Ten Potential Biotype-specific peaks. 
Peaks at m/z (A) 2512(B) 5028, and (C) 4682 were detected only in group 2 isolates. Peaks at m/z (D) 
3411, and (E) 6823 were detected only in group 3 isolates. Peaks at m/z (F) 5970 were detected in 
group 3 isolates, group 4 isolates and reference strain biovar1. Peaks at m/z (G) 3663 and (H) 7326 
were detected in group 4 isolates, and reference strain biovar1.Peaks at m/z (G) 3678 and (H) 7356 
were detected in group 1 isolates, group 2 isolates, and reference strain biovar2. 
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Figure 4.2: Representative Sections of the mass spectral profiles. Representative 
Sections of the mass spectral profiles for the reference strains and clinical isolates. Four distinct marker 
peak profiles showing marker peaks at m/z 4682, 5028, 5970, 6823, 7326 and 7356. 
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Figure 4.3: Gel view representation. 
Gel view representation of the 63 B. melitensis isolates and the two reference stains (NCTC10094 and 
10508).The mass spectral profiles of the four groups were evident on gel view created with the peaks 
of the strains using Biotyper 3.0 software. For example, the peak at m/z 7356 was consistently present 
in the spectra of MALDI-type 2, while it was absent in the others and was therefore incorporated into 
the typing scheme 
 
4.4 Molecular Typing 
4.4.1 PCR amplification and Gel Visualization 
Three different band profiles (Figure 4.4) were obtained and were interpreted 
as per manufacturer's guidelines. Biotype 1 amplified one fragments of 564 bp; 
biotype 2 amplified three fragments of 176, 302 and 564 bp; and biotype 3 
amplified two fragments of 176 and 564 bp. 
 
         
Maldi-type2 
Maldi-type1 
Maldi-type3 
7356 
6823 
7326 
5970 
5970 
5028 
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Of the total; 63 clinical isolates, 32 isolates (50.8%) were identified as B. 
melitensis biotype 2 and 31 (49.2%) as, B. melitensis biotype 3 (Table 4.6). 
Standard strains for biotype 1 and 2 were included in each run. 
Agarose gel electrophoresis images for all B. melitensis isolates included in the 
study are shown in Appendix K. 
Table 4.6: Summary of Molecular Typing Results 
 
Gel electrophoresis 
bands 
 
Biotype 176 302 564 
Number of iso-
lates 
B. melitensis biotype 1 - - + - 
B. melitensis biotype 2 + + + 32 (50.8%) 
B. melitensis biotype 3 + - + 31 (49.2%) 
 
 
Figure 4.4: Representative image of PCR products of B. melitensis biotypes 
resolved on agarose gels. 
Lanes 1-12, clinical isolates from BRUC (37_48).Lane 13, B. melitensis biotype 1 
(NCTC10094), Lane 14, B. melitensis biotype 2 (NCTC10508). 
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4.4.2 Correlation between Serotyping, MALDI-typing and PCR:  
MALDI-types were correlated with serotypes. Within MALDI-type1; 71.42% 
were found to be serotype 1 and 28.58% serotype3. Within MALDI-type 2, 
40.6% were found to be serotype 1; 43.7% serotype 2; and 15.6% serotype 3. 
All isolates within MALDI-type 3 were found to be serotype1 (Table 4.7). 
Table4.7: Correlation between Serotyping and MALDI-typing results 
 
 
MALDI-type 
As per matching with 
reference strains 
Biotype 
 as per serology 
Clinical isolates 
(n=63) 
MALDI-type1 
(n=7) 
71.42% Biotype 1 
(n=5) 
28.58% Biotype 2 
(n=2) 
MALDI-type2 
(n=32) 
 
40.6% Biotype 1 
(n=13) 
15.6% Biotype 2 
(n=14) 
15.6% Biotype 3 
(n=5) 
MALDI-type3 
(n=24) 
100% Biotype 1 
(n=24) 
 
Results from MALDI-TOF MS typing were compared to reference typing by 
PCR. Isolates with MALDI-type 2 (n=32) were confirmed as B. melitensis bio-
type 2, while isolates with MALDI-type 3 (n=24) and MALDI-type1 (n=7) were 
B. melitensis biotype 3(Table 4.8). 
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Table 4.8: Correlation between PCR and MALDI-typing results 
 
MALDI-type 
As per matching with 
reference strains 
Biotype 
 as per PCR 
Clinical isolates 
(n=63) 
MALDI-type1 
(n=7) 
Biotype 3 
MALDI-type2 
(n=32) 
Biotype 2 
MALDI-type3 
(n=24) 
Biotype 3 
Table 4.9: Summary of PCR, MALDI-typing and Serotyping Results 
 
Biotype 
 as per 
PCR 
MALDI-type 
As per matching 
with reference 
strains 
Biotype 
 as per serology 
Clinical 
isolates 
(n=63) 
Biotype2 
(n=32) 
 
MALDI-type2 
(n=32) 
 
Biotype 1 
(n=13) 
Biotype 2 
(n=14) 
Biotype 3 
(n=5) 
Biotype3 
(n=31) 
 
 MALDI-type3 
(n=24) 
 Biotype 1 
(n=24) 
MALDI-type1 
(n=7) 
 
 
Biotype 1 
(n=5) 
Biotype 3 
(n=2) 
 
4.5 MSP Dendrogram Creation 
Using the MSP dendrogram tool of the MALDI Biotyper 3.0 software, all 63 Bru-
cella spectral profiles were clustered into 2 groups corresponding to B. 
melitensis biotype 2 and B. melitensis biotype 3. The eight MALDI-type 2 iso-
lates that showed extra peaks at m/z 4682 and 5028 were ranked among the 
biotype 2 and the seven MALDI-type1 isolates were ranked among the biotype 
3 (Figure 4.5). 
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Figure 4.5: Dendrogram representation of hierarchical cluster analysis of the 
recorded MALDI-types. 
4.6 Statistical analysis 
4.6.1 Mean, standard deviation and coefficient of variation 
Table 4.10: Mean, standard deviation and coefficient of variation of bi-
omarker peaks 
  
MALDI-type1 
MALDI-type1 
MALDI-type1 
MALDI-type3 
MALDI-type3 
  
Peaks of m/z 
4682 5028 5970 6823 7326 7356 
N 8 8 31 24 7 32 
mean  4682.22 5028.75 5970.62 6823.38 7326.12 7356.08 
SD 1.487 1.6809 1.6763 2.1015 1.2788 2.5756 
CV 0.0317% 0.0334% 0.0280% 0.0308% 0.0175% 0.0350% 
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4.6.2 Marker Peaks Frequencies 
Peak at m/z 7356 was present in 100% of biotype 2 spectra while peaks at m/z 
5028 and 4862 were present only in 25% of biotype 2 spectra. None of these 
peaks were present in biotype3 spectra. Peaks at m/z 5970, 6823, and 7326 
were present in biotype 3 in frequencies of 100%, 77.4% and 22.6% respec-
tively and were absent in biotype 2 (Figure 4.6). 
 
Figure4.6: Marker peaks frequencies in B. melitensis biotype 2 and 3. 
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4.6.3 Kappa measure of agreement 
When agreement between results of serotyping, MALDI-typing and molecular 
typing were computed using Kappa measure of agreement, a very low level of 
agreement (Kappa 0.076) was found between Maldi-typing and serotyping re-
sults. However, a strong agreement (Kappa 0.8) was found between MALDI-
typing and molecular typing, the reference methodology (Appendix M and N). 
4.6.4 Pearson chi-square test, Phi and Cramer's V 
When the associations were calculated using Pearson chi-square test and Fish-
er's Exact Test, the marker peaks at m/z 7356 (𝜒2 63, n= 32, df1, P<0.001), at 
m/z 4682 and 5028 (𝜒28.877, n = 8, df1, P 0.003) showed strong evidence of 
association for biotype 2. Strong evidence of association was also found for the 
presence of the marker peak at m/z 5970 for biotype 3 (𝜒2 63, n= 31, df1, 
P<0.001). In addition, the marker peak at m/z 6823 (𝜒2 40, n = 24, df1, 
P<0.001) and peaks at m/z 7326 (𝜒2 8.129, n = 7, df1, P = 0.003), showed evi-
dence of association for biotype 3. 
When Phi coefficient and Cramer’s V were computed to compare the strength 
of association between the marker peaks and biotypes, complete association 
was found between the marker peaks at m/z 7356 and biotype 2and between 
the marker peak at m/z 5970 and  biotype 3 with Phi coefficient and Cramer’s 
V equal to1 (Appendix O).  
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CHAPTER 5 DISCUSSION 
5.1 Discussion 
The aim of this study was to evaluate MALDI–TOF MS as a safe, rapid, and reli-
able tool for typing of B. melitensis. A total of 63 clinical isolates recovered from 
positive cultures collected between 2012 and 2013 and presumptively identi-
fied as Brucella species by conventional methods were included in the study. 
The study isolates were identified as B. melitensis by Vitek 2 Compact  with a 
probability of 99% and further classified with monospecific Brucella antisera 
into biotype 1 (66.66%), biotype 2 (22.22%), and biotype 3 (11.11%).  
The 63 isolates were then identified by MALDI-TOF MS against the newly con-
structed Brucella library as well as the Brucella database provided by the Spe-
cial Pathogen Branch at CDC (Atlanta, USA). All Brucella isolates were identi-
fied as B. melitensis with a log values of >2.30, indicating highly probable spe-
cies identification. Inconsistent results were obtained at the strain level. Our 
findings were consistent with previous studies that infer the reliability of 
MLADI-TOF MS for genus and species level identification of Brucella but not at 
strain level (Ferreira et al., 2010 and Lista et al., 2011). A more recent study 
reported that MALDI could  reliably identify 92% of the Brucella isolates at 
species level,  but incorrect biotype assignments were frequently found 
(Karger et al., 2013).  Characterization at the strain level has proved to be more 
elusive. Several studies have reported an inability to characterize bacteria be-
low the species level (Lasch et al., 2014 , Rim et al., 2015 & Lista et al., 2011). 
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However,  the approach of identifying unique and reproducible peaks (m/z 
values) for different strains was proven to be successful in strain typing in 
Campylobacter and Salmonella ( Zautner et al., 2013 & Dieckmann & Malorny, 
2011). 
In this study, we attempted strain level identification by screening the gener-
ated spectra for biotype-specific marker peaks. We were able to identify six 
promising unique marker peaks at m/z 4682, 5028, 5970, 6823, 7326, and 
7356. The different combinations of the presence or absence of these peaks 
grouped the study isolates into four groups, each with distinct marker peak 
profile. After the comparison of these profiles with the reference strains, three 
MALDI-types were identified. These findings were revealed in gel separation 
view (MALDI-TOF MS) that showed the different mass spectral patterns. 
MALDI-types were correlated with serotypes obtained earlier in the study. Re-
sults were found to be inconsistent with a very low Kappa agreement (0.076). 
Within MALDI-type1; 71.42% were found to be serotype 1 and 28.58% sero-
type3. Within MALDI-type 2, 40.6% were found to be serotype 1; 43.7% sero-
type 2; and 15.6% serotype 3. All isolates within MALDI-type 3 were found to 
be serotype1.  
In order to better resolve the conflicting results, we turned to molecular ap-
proaches. Molecular typing was carried out using B. melitensis biotype typing 
PCR kit. PCR showed the presence of only two biotypes, B. melitensis biotype 2 
(n=32) and B. melitensis biotype 3 (n=31).   When genotype correlation of the 
observed MALDI-types was carried out, it was found that isolates with MALDI-
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type 2 (n=32) were substantially interchangeable with B. melitensis biotype 2 
while isolates with MALDI -type 3 (n=24) as well as MALDI-type1 (n=7) were 
genotyped as B. melitensis biotype3. Kappa agreement between PCR and 
MALDI-typing was found to be 0.8 indicating a strong agreement between the 
two methods. 
Our findings determines that MALDI-typing is comparable to PCR, the refer-
ence methodology, but not to serotyping.  The inconsistence between the sero-
typing and other typing methods (MALDI typing and PCR) might be related to 
the well-known cross reactivity of serotyping antisera. Difficulties in conven-
tional biotyping characterization of B. melitensis strains have already been re-
ported (Sayan et al., 2009 &  European Commission, 2001). 
Discrepancies between MALDI-typing and PCR were found only in 7 out of the 
63 tested Brucella isolate. These seven isolates were identified as B.melitensis 
biotype 3 by PCR but were assigned to MALDI-type 1 as per the observed sim-
ilarity of their marker peak profiles with the profile of biotype 1 reference 
strain (NCTC 10094). Similarity was based on the presence of marker peaks at 
m/z 5970 and 7326 in both profiles and their absence in others except for 
MALDI-type 3 that showed the presence of peak at m/z 5970.  However , San-
drin et al. (2012)  infer that the approach of strain identification by comparing 
its peak profile to a reference strain often requires analysis of the entire spec-
trum rather than the analysis of the presence or absence of one or a few bi-
omarker peaks (Sandrin et al., 2012). Thus, marker peak based approach can 
be used to differentiate strains into different groups rather than identifying 
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them. Furthermore, the presence of peak at m/z 7326 in the spectrum of bio-
type 1 reference strain (NCTC 10094) doesn’t necessarily prove that it is bi-
omarker peak for biotype 1 unless we study more biotype 1 isolates which 
could not be done in this study since all the isolates were either biotype 2 or 3. 
On the other hand, the presence of peak at m/z 7326 in the spectrum of bio-
type1 reference strain doesn’t rule out the possibility of being common peak 
for biotype 1 and 3. This possibility could not be assessed in this study since 
we lack biotype 3 reference strain. We believe that if we had the peak profile 
of biotype 3  reference strain and if we had the chance to analyze biotype 1 
isolates, presumably specific marker peaks might be identified making the dis-
crimination between biotype 1 and 3 more prominent. However, by refereeing 
to the results obtained by Ferreira et al (2010), the peak at m/z 7326 was 
found to be present in both B.melitensis biotype 1 and 3 reference strains indi-
cating that it is a common peak rather than biotype1-specific peak. Consider-
ing this finding, genotype correlation of MALDI-TOF MS typing was reassessed 
as per the four marker peak profiles rather than the three MALDI-types. An 
interesting result was obtained when a detailed comparative analysis of the 
biomarkers corresponding to different biotypes was performed. It was 
observed that the mass spectral profile that share the marker peak at m/z 
7356, present in groups 1 and 2, were genotyped as biotype 2. the mass spec-
tral profile that share the marker peak at m/z 5970, present in groups 3 and 4, 
were genotyped as biotype 3. These findings indicate that the peak at m/z 
7356 is biotype2-specific and 5970 is biotype3-specific. 
 57 
 
Using the MSP dendrogram tool of the MALDI Biotyper 3.0 software, all study 
isolates were accurately clustered into 2 groups corresponding to B. melitensis 
biotype 2 and B. melitensis biotype 3. The eight MALDI-type 2 isolates that 
showed extra peaks at m/z 4682 and 5028 were accurately ranked among the 
biotype 2 and the seven MALDI-type1 isolates were accurately ranked among 
the biotype 3. This suggest that marker peaks at m/z 4682 and 5028 could be 
used for further classification of biotype 2 variants  and marker peaks at 6823 
and 7326 for further classification of biotype 3 variants.  
Based on the findings in this study, we suggest that MALDI-TOF MS is a very 
promising tool for biotyping of B. melitensis. Using MALDI-TOF MS we were 
able to differentiate between   two B. melitensis biotypes, biotype 2 and 3, 
based on the identification of their biotype-specific peaks, but unfortunately 
we were unable to define the marker peak (or peaks) for biotype 1 since none 
of the clinical isolates were of biotype 1 and due to the fact that we cannot rely 
on the analysis of a single spectra (the reference strain) to define the marker 
peaks.  
Further studies are still needed to fully explore the utility of MALDI-TOF MS 
for identification at strain level. As per our findings in this study, MALDI-TOF 
was able to differentiate two different patterns of each biotype indicating that 
MALDI might have the differentiation power beyond the strain level identifi-
cation. Future studies to define the potential biotype 1-specific marker peak 
(or peaks) are to be conducted.  Studies should address the evaluation of in-
terlaboratory reproducibility. Whether these biotype-specific peaks, detected 
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in this study, are specific for Qatar isolates only and related to the geographic 
character of the Brucella strains should be clarified with greater numbers of B. 
melitensis isolates from all over the world. 
Our findings infer that B. melitensis biotype 2 and biotype 3 are equally distrib-
uted in Qatar.  Studies about the prevalence of brucellosis in neighboring coun-
tries like Saudi Arabia revealed that the B. melitensis biotype 3 is the prevalent 
serotype (Memish, 2001). However Prevalence of B. melitensis biotype 1 was 
reported from Oman (Adam & El-Rashied, 2013). 
5.2 Limitations 
There are some limitations to this study 
 We didn’t include B. melitensis Ether biotype 3 (NCTC10509) standard 
strain in our study, as it was not available with Culture Collections at Pub-
lic Health England, UK and they are the only supplier of standard reference 
strains (NCTC) of Brucella. 
 Due to unavailability of biotype 1 isolates (clinical) in Qatar, we were not 
able to generate biotype 1 specific MALDI-type marker peak profile.  
 Low sample size: We believe that in order to be able to provide a robust 
typing tool, more number of strains with different Brucella species should 
be analyzed and MALDI-type profiles generated, should be incorporated 
into the typing scheme. 
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CHAPTER 6 CONCLUSION 
Human brucellosis in Qatar is exclusively caused by B. melitensis with equal 
distribution of biotype 2 and biotype 3.  The detection of predominant species 
and biotype is the major step to develop control strategies for brucellosis.  
We established a preliminary MALDI-TOF-based B. melitensis typing scheme 
that allows accurate and reproducible discrimination of the 2 prevalent bio-
types. Therefore, our results indicate that MALDI-TOF has the potential to be-
come a rapid first-line screening tool for prediction of biotypes and can be used 
as tool for epidemiological studies and outbreak investigation. MALDI-TOF MS 
Strain identification using the unique protein profiles can be achieved with 
minimal time, labor and cost, making it an attractive alternative to the rela-
tively high investment required for other molecular settings. 
To our knowledge, this is the first study employing the MALDI-TOF MS tech-
nique for the in-depth analysis of B. melitensis. 
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APPENDIX C: INTERPRETATION OF SEROTYPING 
Table 1: Characters Differentiating the Species and Biotypes of Brucella. 
Species 
Bioty-
pe 
CO
2 
H2S 
Ure-
ase 
Growth on 
Media 
Containing 
Agglutination with 
Monospecific Anti-
sera 
thio-
nin* 
fuch-
sin* 
A M R 
B. melitensis 
1 - - + + + - + - 
2 - - + + + + - - 
3 - - + + + + + - 
B. abortus 
1 (+) + + - + + - - 
2 (+) + + - - + - - 
3 (+) + + + + + - - 
4 (+) + + - (+) - + - 
5 - - + + + - + - 
6 - - + + + + - - 
9 - + + + + - + - 
B. suis 
1 - + + + (-) + - - 
2 - - + + - + - - 
3 - - + + + + - - 
4 - - + + (-) + + - 
5 - - + + - - + - 
B. neotomae - - + + - - + - - 
B. canis - - - + + (-) - - + 
B. ovis - + - - + (-) - - + 
*Concentration = 1/50 000 w/v 
(+) = Most strains positive (-) = Most strains negative 
Adapted from Brucellosis in humans and animals.2006.Publications of the 
World Health Organization. 
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APPENDIX D: RESULTS OF VITEK AND SEROTYPING 
Table 2: Identification and typing of Brucella isolates by conventional meth-
ods. 
Analyte 
Name 
Vitek Serology 
Identification Probability Confidence A M Serotype 
BRUC01 B. melitensis 99% Excellent + - Serotype2 
BRUC02 B. melitensis 99% Excellent + - Serotype2 
BRUC03 B. melitensis 99% Excellent - + Serotype1 
BRUC04 B. melitensis 99% Excellent - + Serotype1 
BRUC05 B. melitensis 99% Excellent - + Serotype1 
BRUC06 B. melitensis 99% Excellent - + Serotype1 
BRUC07 B. melitensis 99% Excellent + - Serotype2 
BRUC08 B. melitensis 99% Excellent + - Serotype2 
BRUC09 B. melitensis 99% Excellent + - Serotype2 
BRUC10 B. melitensis 99% Excellent - + Serotype1 
BRUC11 B. melitensis 99% Excellent + - Serotype2 
BRUC12 B. melitensis 99% Excellent + - Serotype2 
BRUC13 B. melitensis 99% Excellent + + Serotype3 
BRUC14 B. melitensis 99% Excellent - + Serotype1 
BRUC15 B. melitensis 99% Excellent - + Serotype1 
BRUC16 B. melitensis 99% Excellent - + Serotype1 
BRUC17 B. melitensis 99% Excellent - + Serotype1 
BRUC18 B. melitensis 99% Excellent - + Serotype1 
BRUC19 B. melitensis 99% Excellent - + Serotype1 
BRUC20 B. melitensis 99% Excellent - + Serotype1 
BRUC21 B. melitensis 99% Excellent - + Serotype1 
BRUC22 B. melitensis 99% Excellent + - Serotype2 
BRUC23 B. melitensis 99% Excellent - + Serotype1 
BRUC24 B. melitensis 99% Excellent + + Serotype3 
BRUC25 B. melitensis 99% Excellent - + Serotype1 
BRUC26 B. melitensis 99% Excellent - + Serotype1 
BRUC27 B. melitensis 99% Excellent - + Serotype1 
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Analyte 
Name 
Vitek Serology 
Identification Probability Confidence A M Serotype 
BRUC28 B. melitensis 99% Excellent - + Serotype1 
BRUC29 B. melitensis 99% Excellent - + Serotype1 
BRUC30 B. melitensis 99% Excellent - + Serotype1 
BRUC31 B. melitensis 99% Excellent - + Serotype1 
BRUC32 B. melitensis 99% Excellent - + Serotype1 
BRUC33 B. melitensis 99% Excellent - + Serotype1 
BRUC34 B. melitensis 99% Excellent - + Serotype1 
BRUC35 B. melitensis 99% Excellent - + Serotype1 
BRUC36 B. melitensis 99% Excellent + + Serotype3 
BRUC37 B. melitensis 99% Excellent - + Serotype1 
BRUC38 B. melitensis 99% Excellent + - Serotype2 
BRUC39 B. melitensis 99% Excellent + + Serotype3 
BRUC40 B. melitensis 99% Excellent - + Serotype1 
BRUC41 B. melitensis 99% Excellent - + Serotype1 
BRUC42 B. melitensis 99% Excellent - + Serotype1 
BRUC43 B. melitensis 99% Excellent - + Serotype1 
BRUC44 B. melitensis 99% Excellent + - Serotype2 
BRUC45 B. melitensis 99% Excellent - + Serotype1 
BRUC46 B. melitensis 99% Excellent + - Serotype2 
BRUC47 B. melitensis 99% Excellent - + Serotype1 
BRUC48 B. melitensis 99% Excellent - + Serotype1 
BRUC49 B. melitensis 99% Excellent - + Serotype1 
BRUC50 B. melitensis 99% Excellent - + Serotype1 
BRUC51 B. melitensis 99% Excellent - + Serotype1 
BRUC52 B. melitensis 99% Excellent - + Serotype1 
BRUC53 B. melitensis 99% Excellent - + Serotype1 
BRUC54 B. melitensis 99% Excellent + + Serotype3 
BRUC55 B. melitensis 99% Excellent + + Serotype3 
BRUC56 B. melitensis 99% Excellent - + Serotype1 
BRUC57 B. melitensis 99% Excellent + - Serotype2 
BRUC58 B. melitensis 99% Excellent + - Serotype2 
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Analyte 
Name 
Vitek Serology 
Identification Probability Confidence A M Serotype 
BRUC59 B. melitensis 99% Excellent - + Serotype1 
BRUC60 B. melitensis 99% Excellent - + Serotype1 
BRUC61 B. melitensis 99% Excellent + - Serotype2 
BRUC62 B. melitensis 99% Excellent - + Serotype1 
BRUC63 B. melitensis 99% Excellent + + Serotype3 
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APPENDIX E: MALDI-TOF MS IDENTIFICATION  
Table3: MALDI-TOF MS Identification Results. 
Bruker Daltonics MALDI Biotyper Classification Results against the newly 
constructed library. 
Analyte 
Name 
Organism (best 
match) 
Score 
Value 
Organism (second 
best match) 
Score 
Value 
BRUC1 B. melitensis 2.582 B. melitensis 2.494 
BRUC2 B. melitensis 2.537 B. melitensis 2.428 
BRUC3 B. melitensis 2.385 B. melitensis 2.381 
BRUC4 B. melitensis 2.6 B. melitensis 2.57 
BRUC5 B. melitensis 2.626 B. melitensis 2.62 
BRUC6 B. melitensis 2.578 B. melitensis 2.524 
BRUC7 B. melitensis 2.559 B. melitensis 2.479 
BRUC8 B. melitensis 2.537 B. melitensis 2.459 
BRUC9 B. melitensis 2.505 B. melitensis 2.448 
BRUC10 B. melitensis 2.596 B. melitensis 2.568 
BRUC11 B. melitensis 2.568 B. melitensis 2.454 
BRUC12 B. melitensis 2.373 B. melitensis 2.352 
BRUC13 B. melitensis 2.511 B. melitensis 2.48 
BRUC14 B. melitensis 2.542 B. melitensis 2.519 
BRUC15 B. melitensis 2.671 B. melitensis 2.578 
BRUC16 B. melitensis 2.654 B. melitensis 2.633 
BRUC17 B. melitensis 2.589 B. melitensis 2.558 
BRUC18 B. melitensis 2.614 B. melitensis 2.589 
BRUC19 B. melitensis 2.646 B. melitensis 2.507 
BRUC20 B. melitensis 2.676 B. melitensis 2.673 
BRUC21 B. melitensis 2.624 B. melitensis 2.596 
BRUC22 B. melitensis 2.585 B. melitensis 2.498 
BRUC23 B. melitensis 2.641 B. melitensis 2.602 
BRUC24 B. melitensis 2.636 B. melitensis 2.597 
BRUC25 B. melitensis 2.609 B. melitensis 2.568 
BRUC26 B. melitensis 2.662 B. melitensis 2.518 
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Analyte 
Name 
Organism (best 
match) 
Score 
Value 
Organism (second 
best match) 
Score 
Value 
BRUC27 B. melitensis 2.629 B. melitensis 2.607 
BRUC28 B. melitensis 2.647 B. melitensis 2.554 
BRUC29 B. melitensis 2.616 B. melitensis 2.539 
BRUC30 B. melitensis 2.602 B. melitensis 2.582 
BRUC31 B. melitensis 2.622  B. melitensis 2.561 
BRUC32 B. melitensis 2.662  B. melitensis 2.557 
BRUC33 B. melitensis 2.639  B. melitensis 2.587 
BRUC34 B. melitensis 2.605  B. melitensis 2.54 
BRUC35 B. melitensis 2.619  B. melitensis 2.585 
BRUC36 B. melitensis 2.604 B. melitensis 2.544 
BRUC37 B. melitensis 2.636 B. melitensis 2.544 
BRUC38 B. melitensis 2.54 B. melitensis 2.46 
BRUC39 B. melitensis 2.638 B. melitensis 2.625 
BRUC40 B. melitensis 2.627 B. melitensis 2.598 
BRUC41 B. melitensis 2.622 B. melitensis 2.562 
BRUC42 B. melitensis 2.622 B. melitensis 2.615 
BRUC43 B. melitensis 2.601 B. melitensis 2.55 
BRUC44 B. melitensis 2.591 B. melitensis 2.528 
BRUC45 B. melitensis 2.627 B. melitensis 2.598 
BRUC46 B. melitensis 2.546 B. melitensis 2.494 
BRUC47 B. melitensis 2.617 B. melitensis 2.565 
BRUC48 B. melitensis 2.633 B. melitensis 2.633 
BRUC49 B. melitensis 2.563 B. melitensis 2.556 
BRUC50 B. melitensis 2.535 B. melitensis 2.503 
BRUC51 B. melitensis 2.601 B. melitensis 2.576 
BRUC52 B. melitensis 2.579 B. melitensis 2.454 
BRUC53 B. melitensis 2.604 B. melitensis 2.564 
BRUC54 B. melitensis 2.637 B. melitensis 2.548 
BRUC55 B. melitensis 2.588 B. melitensis 2.558 
BRUC56 B. melitensis 2.582 B. melitensis 2.541 
BRUC57 B. melitensis 2.627 B. melitensis 2.556 
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Analyte 
Name 
Organism (best 
match) 
Score 
Value 
Organism (second 
best match) 
Score 
Value 
BRUC58 B. melitensis 2.638 B. melitensis 2.555 
BRUC59 B. melitensis 2.635 B. melitensis 2.604 
BRUC60 B. melitensis 2.632 B. melitensis 2.542 
BRUC61 B. melitensis 2.647 B. melitensis 2.566 
BRUC62 B. melitensis 2.647 B. melitensis 2.566 
BRUC63 B. melitensis 2.614 B. melitensis 2.571 
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APPENDIX F: MALDI-TOF MS TYPING RESULTS  
Table 4:  MALDI-TOF MS Typing Results. 
MALDI- typing Results. As per the marker peaks. The study isolates were di-
vided into four distinct marker peak profiles and three main MALDI-types. 
Isolate # 
Peaks (m/z) 
MALDI-type 
4682 5028 5970 6823 7326 7356 
NCTC10094 
Biotype 1 
- - + - + - 
MALDI-type1 
NCTC10508 
Biotype 2 
- - - - - + 
MALDI-type2 
BRUC02 - -  - - + 
MALDI-type2 
BRUC04 - - - - - + 
BRUC07 - - - - - + 
BRUC10 - - - - - + 
BRUC11 - - - - - + 
BRUC12 - - - - - + 
BRUC13 - - - - - + 
BRUC14 - - - - - + 
BRUC26 - - - - - + 
BRUC28 - - - - - + 
BRUC31 - - - - - + 
BRUC38 - - - - - + 
BRUC39 - - - - - + 
BRUC41 - - - - - + 
BRUC43 - - - - - + 
BRUC45 - - - - - + 
BRUC47 - - - - - + 
BRUC52 - - - - - + 
BRUC54 - - - - - + 
BRUC55 - - - - - + 
BRUC58 - - - - - + 
BRUC59 - - - - - + 
BRUC60 - - - - - + 
BRUC63 - - - - - + 
BRUC01 + + - - - + 
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Isolate # 
Peaks (m/z) 
MALDI-type 
4682 5028 5970 6823 7326 7356 
BRUC08 + + - - - + 
BRUC09 + + - - - + 
MALDI-type2 
BRUC22 + + - - - + 
BRUC44 + + - - - + 
BRUC46 + + - - - + 
BRUC57 + + - - - + 
BRUC61 + + - - - + 
BRUC03 - - + + - - 
MALDI-type3 
BRUC05 - - + + - - 
BRUC06 - - + + - - 
BRUC15 - - + + - - 
BRUC17 - - + + - - 
BRUC18 - - + + - - 
BRUC20 - - + + - - 
BRUC21 - - + + - - 
BRUC23 - - + + - - 
BRUC25 - - + + - - 
BRUC27 - - + + - - 
BRUC30 - - + + - - 
BRUC32 - - + + - - 
BRUC33 - - + + - - 
BRUC35 - - + + - - 
BRUC37 - - + + - - 
BRUC40 - - + + - - 
BRUC42 - - + + - - 
BRUC48 - - + + - - 
BRUC49 - - + + - - 
BRUC51 - - + + - - 
BRUC53 - - + + - - 
BRUC56 - - + + - - 
BRUC62 - - + + - - 
BRUC16 - - + - + - MALDI-type1 
BRUC19 - - + - + - 
BRUC24 - - + - + - 
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Isolate # 
Peaks (m/z) 
MALDI-type 
4682 5028 5970 6823 7326 7356 
BRUC29 - - + - + - 
BRUC34 - - + - + - MALDI-type1 
BRUC36 - - + - + - 
BRUC50 - - + - + - 
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APPENDIX G: REPRESENTATIVE SECTIONS OF GROUP (1) 
MASS SPECTRAL PROFILE 
 
 
1 
2 
3 
5 
4 
6 
* 
* 
* 
* 
* 
* 
 79 
 
 
 
7393.79
5169.38
5523.75
7512.42
7055.746283.61 6673.514770.22
4409.63
5871.11 6167.83 7657.345040.39
5605.23
6946.455686.46
5357.93
BRUC38 0:G5 MS, Smoothed, BaselineSubtracted
0.00
0.25
0.50
0.75
1.00
1.25
4x10
In
te
n
s
. 
[a
.u
.]
7357.64
4852.45
5169.77
7512.58
6673.95
7042.14
4770.31 6284.014409.64
5871.37
5040.66 6877.33 7657.185542.01
BRUC39 0:G8 MS, Smoothed, BaselineSubtracted
0.00
0.25
0.50
0.75
1.00
1.25
4x10
In
te
n
s
. 
[a
.u
.]
4537.13
7355.73
4893.73
5168.33
7510.82
6672.02
7040.44
6531.144769.11
4408.66 6282.125869.66 6944.95 7655.425540.13
5039.28 6030.57 6791.57
BRUC4 0:A7 MS, Smoothed, BaselineSubtracted
0.00
0.25
0.50
0.75
1.00
1.25
4x10
In
te
n
s
. 
[a
.u
.]
4500 5000 5500 6000 6500 7000 7500
m/z
 
9 
8 
10 
12 
11 
7 
* 
* 
* 
*
* 
* 
 80 
 
 
 
7357.12
4895.01
5169.31
7512.07
6673.48
7041.74
6283.574770.30
5870.954409.54 6946.275541.75
7657.366167.485040.32
6793.45
4788.77
5687.36
BRUC41 0:G11 MS, Smoothed, BaselineSubtracted
0.0
0.5
1.0
1.5
4x10
In
te
n
s
. 
[a
.u
.]
7356.70
4537.72 4851.67
5169.00
6672.79
7511.61
7054.68
6283.19
6532.044769.65
4408.96 5870.36 6030.27 7656.24
5039.81 5604.39 6945.71
BRUC43 0:H4 MS, Smoothed, BaselineSubtracted
0.0
0.5
1.0
1.5
4x10
In
te
n
s
. 
[a
.u
.]
4537.71 7356.61
4894.25
5168.90
7511.296672.75 7054.75
6282.934769.61
4409.04
7452.95
5870.32 7656.346945.646167.075039.36
BRUC45 0:H8 MS, Smoothed, BaselineSubtracted
0.0
0.5
1.0
1.5
4x10
In
te
n
s
. 
[a
.u
.]
4500 5000 5500 6000 6500 7000 7500
m/z
4894.10 7355.95
5168.67
7511.19
7040.786672.28
4769.41
4408.75 6282.595870.05
6945.405541.145039.68 6030.39 7655.76
5357.34
BRUC47 0:A3 MS, Smoothed, BaselineSubtracted
0.0
0.2
0.4
0.6
0.8
1.0
4x10
In
te
n
s
. 
[a
.u
.]
4538.06
7357.204894.60
5169.31
7511.97
6673.49
7041.62
4769.95
7454.98
6283.615871.05 6876.764409.19
7657.025541.57
5040.14
BRUC52 0:B4 MS, Smoothed, BaselineSubtracted
0.0
0.2
0.4
0.6
0.8
1.0
4x10
In
te
n
s
. 
[a
.u
.]
4538.07
7357.12
4852.09
5169.40
7512.05
6673.43
7055.44
6283.62 6532.584770.02
5871.044409.35
7656.906946.365541.78 6166.835357.565040.12
BRUC54 0:B7 MS, Smoothed, BaselineSubtracted
0.0
0.2
0.4
0.6
0.8
1.0
1.2
4x10
In
te
n
s
. 
[a
.u
.]
4500 5000 5500 6000 6500 7000 7500
m/z
13 
15 
14 
16 
18 
17 
* 
* 
* 
* 
* 
* 
 81 
 
 
 
Figure 1: Representative Sections of Group 1 mass spectral profile. 
Group 1(n=24) had only one marker peak at m/z 7356. 
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APPENDIX H: REPRESENTATIVE SECTIONS OF GROUP (2) 
MASS SPECTRAL PROFILE 
 
 
Figure 2: Representative Sections of Group 2 mass spectral profile. 
Group 2(n=8) had marker peaks at m/z 4682, 5028 and 7356. 
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APPENDIX I: REPRESENTATIVE SECTIONS OF GROUP (3) 
MASS SPECTRAL PROFILE 
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Figure 3: Representative Sections of Group 3 mass spectral profile. 
Group 3(n=24) had marker peaks at m/z 5970 and 6823. 
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APPENDIX J: REPRESENTATIVE SECTIONS OF GROUP (4) 
MASS SPECTRAL PROFILE 
 
 
 
Figure 4: Representative Sections of Group 3 mass spectral profile. Group 
4(n=7) had marker peaks at m/z 5970 and 7326. 
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APPENDIX K: PCR PRODUCTS OF B. MELITENSIS BIOTYPES 
RESOLVED ON AGAROSE GELS 
Figure 5-1 
Figure 5-2 
Figure 5-3 
Figure 5-4 
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Figure 5-5 
Figure 5-6 
Figure 5-7 
Figure 5:  PCR products of B. melitensis biotypes resolved on agarose gels. 
 K1 to K7: For all images, Lanes 1-12 represent the clinical isolates BRUC (01 -63), Lane 13, B. melitensis 
biotype 1 (NCTC10094), Lane 14, B. melitensis biotype 2 (NCTC10508). 5-1 and 5-2 represent the same 
samples run in duplicate, each time with different reference strain. 5-7 represent repeated results for 
MALDI-type 1 as well as BRUC61-63. 
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APPENDIX L: COROLATION OF MALDI-TYPING, SEROTYPING, 
AND MOLECULAR TYPING  
Table 5:  Correlation of MALDI-typing, Serotyping, and Molecular typing.  
Isolate # 
Peaks (m/z) 
MALDI PCR Serotype 
4682 5028 5970 6823 7326 7356 
NCTC10094  
Biotype1 
- - + - + - 
Maldi-type1 biotype1 Serotype1 
NCTC10508 
Biotype2 
- - - - - + 
Maldi-type 2 biotype 2 Serotype2 
BRUC02 - - - - - + Maldi-type 2 biotype 2 Serotype2 
BRUC04 - - - - - + Maldi-type 2 biotype 2 Serotype1 
BRUC07 - -  - - + Maldi-type 2 biotype 2 Serotype2 
BRUC10 - - - - - + Maldi-type 2 biotype 2 Serotype1 
BRUC11 - - - - - + Maldi-type 2 biotype 2 Serotype2 
BRUC12 - - - - - + Maldi-type 2 biotype 2  Serotype2 
BRUC13 - - - - - + Maldi-type 2 biotype 2 Serotype3 
BRUC14 - - - - - + Maldi-type 2 biotype 2 Serotype1 
BRUC26 - - - - - + Maldi-type 2 biotype 2 Serotype1 
BRUC28 - - - - - + Maldi-type 2 biotype 2 Serotype1 
BRUC31 - - - - - + Maldi-type 2 biotype 2 Serotype1 
BRUC38 - - - - - + Maldi-type 2 biotype 2 Serotype2 
BRUC39 - - - - - + Maldi-type 2 biotype 2 Serotype3 
BRUC41 - - - - - + Maldi-type 2 biotype 2 Serotype1 
BRUC43 - - - - - + Maldi-type 2 biotype 2  Serotype1 
BRUC45 - - - - - + Maldi-type 2 biotype 2 Serotype1 
BRUC47 - - - - - + Maldi-type 2 biotype 2 Serotype1 
BRUC52 - - - - - + Maldi-type 2 biotype 2 Serotype1 
BRUC54 - - - - - + Maldi-type 2 biotype 2  Serotype3 
BRUC55 - - - - - + Maldi-type 2 biotype 2 Serotype3 
BRUC58 - - - - - + Maldi-type 2 biotype 2 Serotype2 
BRUC59 - - - - - + Maldi-type 2 biotype 2 Serotype1 
BRUC60 - - - - - + Maldi-type 2 biotype 2  Serotype1 
BRUC63 - - - - - + Maldi-type 2 biotype 2 Serotype3 
BRUC01 + + - - - + Maldi-type 2 biotype 2 Serotype2 
BRUC08 + + - - - + Maldi-type 2 biotype 2 Serotype2 
BRUC09 + + - - - + Maldi-type 2 biotype 2 Serotype2 
BRUC22 + + - - - + Maldi-type 2 biotype 2  Serotype2 
BRUC44 + + - - - + Maldi-type 2 biotype 2 Serotype2 
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Isolate # 
Peaks (m/z) 
MALDI PCR Serotype 
4682 5028 5970 6823 7326 7356 
BRUC46 + + - - - + Maldi-type 2 biotype 2 Serotype2 
BRUC57 + + - - - + Maldi-type 2 biotype 2 Serotype2 
BRUC61 + + - - - + Maldi-type 2 biotype 2 Serotype2 
BRUC03 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC05 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC06 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC15 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC17 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC18 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC20 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC21 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC23 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC25 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC27 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC30 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC32 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC33 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC35 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC37 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC40 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC42 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC48 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC49 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC51 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC53 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC56 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC62 - - + + - - Maldi-type3 biotype 3 Serotype1 
BRUC16 - - + - + - Maldi-type1 biotype 3 Serotype1 
BRUC19 - - + - + - Maldi-type1 biotype 3 Serotype1 
BRUC24 - - + - + - Maldi-type1 biotype 3 Serotype3 
BRUC29 - - + - + - Maldi-type1 biotype 3 Serotype1 
BRUC34 - - + - + - Maldi-type1 biotype 3 Serotype1 
BRUC50 - - + - + - Maldi-type1 biotype 3 Serotype1 
BRUC36 - - + - + - Maldi-type1 biotype 3 Serotype3 
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APPENDIX M: KAPPA MEASURE OF AGREEMENT (MALDI-
TYPING vs SEROTYPING) 
Table 6:  Kappa measure of agreement; MALDI-typing vs serotyping. 
SERO * MALDI  Cross tabulation 
 Maldi Total 
1 2 3 
sero 1 Count 5 13 24 42 
% within Maldi 71.4% 40.6% 100.0% 66.7% 
2 Count 0 14 0 13 
% within Maldi 0.0% 43.7% 0.0% 20.6% 
3 Count 2 5 0 8 
% within Maldi 28.6% 15.6% 0.0% 12.7% 
Total Count 7 32 24 63 
% within Maldi 100.0 100.0 100.0 100.0% 
 
                                                        
 
 
1 Not assuming the null hypothesis 
2 Using the asymptotic standard error assuming the null hypothesis 
Symmetric Measures 
 Value Asymp. Std. 
1Error1 
Approx. T2 Approx. 
Sig. 
Measure of 
Agreement 
 
 
Kappa 
.076 .053 1.329 .184 
N of Valid Cases 63    
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APPENDIX N: KAPPA MEASURE OF AGREEMENT (MALDI-
TYPING vs PCR) 
Table 7:  Kappa measure of agreement; MALDI-typing vs PCR. 
 MALDI * PCR  Cross tabulation 
  PCR Total 
Biotype 1 Biotype 2 Biotype3 
MALD 
Type1 
Count 0 0 7 7 
% within PCR 0.0% 0.0% 22.6% 11.1% 
Type2 
Count 0 32 0 32 
% within PCR 0.0% 100.0% 0.0% 50.8% 
Type3 
Count 0 0 24 24 
% within PCR 0.0% 0.0% 77.4% 38.1% 
Total 
Count 0 32 31 63 
% within PCR 0.0% 100.0% 100.0% 100.0% 
 
 
Symmetric Measures 
 Value Asymp. Std. 
Error3 
Approx. T4 Approx. 
Sig. 
Measure of Agree-
ment 
Kappa .800 .063 7.536 .000 
N of Valid Cases 63    
                                                        
 
 
3 Not assuming the null hypothesis 
4 Using the asymptotic standard error assuming the null hypothesis 
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APPENDIX O: CHI SQUARE, PHI AND CRAMER'S V 
Associations between the potential marker peaks and B. melitensis biotypes as 
per PCR calculated using Pearson chi-square test. 
Table 8: Associations between Marker Peak at m/z 4682 and B. melitensis bi-
otypes 2& 3 
Crosstab 
 PCR Total 
Biotype 2 Biotype3 
4682 
0 
Count 24 31 55 
% within PCR 75.0% 100.0% 87.3% 
1 
Count 8 0 8 
% within PCR 25.0% 0.0% 12.7% 
Total 
Count 32 31 63 
% within PCR 100.0% 100.0% 100.0% 
Chi-Square Tests 
 Value df Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Pearson Chi-Square 8.877a 1 .003  
Continuity Correction b 6.765 1 .009  
Fisher's Exact Test    .005 
N of Valid Cases 63    
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 3.94. 
b. Computed only for a 2x2 table 
 
Symmetric Measures 
 
Value Approx. Sig. 
Nominal by Nominal Phi -.375 .003 
Cramer's V .375 .003 
N of Valid Cases 63 
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Table 9: Associations between Marker Peak at m/z 5028 and B. melitensis bi-
otypes 2& 3 
Crosstab 
 PCR Total 
Biotype 2 Biotype3 
5028 
0 
Count 24 31 55 
% within PCR 75.0% 100.0% 87.3% 
1 
Count 8 0 8 
% within PCR 25.0% 0.0% 12.7% 
Total 
Count 32 31 63 
% within PCR 100.0% 100.0% 100.0% 
Chi-Square Tests 
 Value df Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Pearson Chi-Square 8.877a 1 .003  
Continuity Correction b 6.765 1 .009  
Fisher's Exact Test    .005 
N of Valid Cases 63    
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 3.94. 
b. Computed only for a 2x2 table 
 
Symmetric Measures 
 
Value Approx. Sig. 
Nominal by Nominal Phi -.375 .003 
Cramer's V .375 .003 
N of Valid Cases 63 
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Table 10: Associations between Marker Peak at m/z 5970 and B. melitensis 
biotypes 2& 3 
Crosstab 
 PCR Total 
Biotype 2 Biotype3 
5970 
0 
Count 32 0 32 
% within PCR 100.0% 0.0% 50.8% 
1 
Count 0 31 31 
% within PCR 0.0% 100.0% 49.2% 
Total 
Count 32 31 63 
% within PCR 100.0% 100.0% 100.0% 
Chi-Square Tests 
 Value df Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Pearson Chi-Square 63.000a 1 .000  
Continuity Correction b 59.063 1 .000  
Fisher's Exact Test    .000 
N of Valid Cases 63    
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 15.25. 
b. Computed only for a 2x2 table. 
 
Symmetric Measures 
 
Value Approx. Sig. 
Nominal by Nominal Phi 1.000 .000 
Cramer's V 1.000 .000 
N of Valid Cases 
63 
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Table 11: Associations between Marker Peak at m/z 6823 and B. melitensis 
biotypes2& 3 
Crosstab 
 PCR Total 
Biotype 2 Biotype3 
6823 
0 
Count 32 7 39 
% within PCR 100.0% 22.6% 61.9% 
1 
Count 0 24 24 
% within PCR 0.0% 77.4% 38.1% 
Total 
Count 32 31 63 
% within PCR 100.0% 100.0% 100.0% 
Chi-Square Tests 
 Value df Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Pearson Chi-Square 40.020a 1 .000  
Continuity Correctionb 36.804 1 .000  
Fisher's Exact Test    .000 
N of Valid Cases 63    
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 11.81. 
b. Computed only for a 2x2 table 
 
Symmetric Measures 
 
Value Approx. Sig. 
Nominal by Nominal Phi .797 .000 
Cramer's V .797 .000 
N of Valid Cases 
63 
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Table 12: Associations between Marker Peak at m/z 7326 and B. melitensis 
biotypes 2& 3 
Crosstab 
 PCR Total 
Biotype 2 Biotype 3 
7326 
0 
Count 32 24 56 
% within PCR 100.0% 77.4% 88.9% 
1 
Count 0 7 7 
% within PCR 0.0% 22.6% 11.1% 
Total 
Count 32 31 63 
% within PCR 100.0% 100.0% 100.0% 
Chi-Square Tests 
 Value df Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Pearson Chi-Square 8.129a 1 .004  
Continuity Correctionb 6.003 1 .014  
Fisher's Exact Test    .005 
N of Valid Cases 63    
 
Symmetric Measures 
 
Value Approx. Sig. 
Nominal by Nominal Phi .359 .004 
Cramer's V .359 .004 
N of Valid Cases 
63 
 
 
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 3.44. 
b. Computed only for a 2x2 table 
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Table 13: Associations between Marker Peak at m/z 7356 and B. melitensis 
biotypes 
Crosstab 
 PCR Total 
Biotype 2 Biotype 3 
7356 
0 
Count 0 31 31 
% within PCR 0.0% 100.0% 49.2% 
1 
Count 32 0 32 
% within PCR 100.0% 0.0% 50.8% 
Total 
Count 32 31 63 
% within PCR 100.0% 100.0% 100.0% 
 
Chi-Square Tests 
 Value df Asymp. 
Sig. (2-
sided) 
 
Pearson Chi-Square 63.000a 1 .000  
Continuity Correctionb 59.063 1 .000  
Fisher's Exact Test    .000 
N of Valid Cases 63    
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 15.25. 
b. Computed only for a 2x2 table 
 
Symmetric Measures 
 
Value Approx. Sig. 
Nominal by Nominal Phi -1.000 .000 
Cramer's V 1.000 .000 
N of Valid Cases 
63 
 
  
 
 
 جامعة قطر
 قسم الدراسات العليا
 والعلومكلية الآداب 
للتعرف على الفصائل المختلفة  )FOT IDLAMتطبيق قياس الطيف الكتلي (
 )sisnetilem .Bلجرثومة الحمى المالطية (
 العلوم الصحيةقسم 
 برنامج العلوم الحيوية الطبية
 مقدمة من
 علا أسعد الشرباصي
  5102 ©علا أسعد الشرباصي
 العلوم / آدابمقدمة لاستيفاء متطلبات درجة الماجستير في 
 5102مايو / آذار 
  
 
 
 خلاصة البحث
ي قطر فأو ما يعرف بحمى البحر المتوسط  تبين في هذه الدراسة أن المسبب الرئيسي لمرض الحمى المالطية 
 وبالأخص فصيلين منها أثبت وجودهما بنسب متساوية هما .B  sisnetilemهي البكتيريا المسماة 
 sisnetilem .Bو حيث أن  عملية التعرف عن الفصائل السائدة من   .B  sisnetilem  3 dna 2 epytoib
، كان هدف هذه الدراسة والتي تعد الأولى  على هذا المرض سيطرةالحجر الزاوية لتطوير استراتيجيات تمثل 
لجرثومة للتعرف على الفصائل المختلفة  SM FOT-IDLAM قياس الطيف الكتلي من نوعها استخدام تقنية
و قد تمكنا من الوصول الى نتيجة وان كانت مبدئية لكنها على درجة عالية من الدقة والقدرة  . sisnetileM .B
على التمييز وبشكل واضح بين الفصيلين الأكثر انتشارا في قطر وذلك باكتشاف اختلافات في الطيف الكتلي 
ه من  سرعة الأداء والدقة مع بما تتميز ب SM FOT-IDLAMلهذه الفصائل. هذاالاكتشاف  يؤهل تقنية 
والمستخدمة   انخفاض سعر التكلفة لأن تكون بديلا ممكنا للتقنيات الجزيئية التي تتميز بتكلفتها المرتفعه نسبيا
 .في الدراسات الوبائية
 
 
